,Start Date,Start Price,End Date,End Price,Weekly Returns,Bin Label,News,Basics
0,2024-11-03,157.59388732910156,2024-11-10,153.0076904296875,-0.029101362858298896,D3,"[{""date"": ""20241104043100"", ""headline"": ""Johnson & Johnson stock underperforms Monday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Monday when compared to competitors""}, {""date"": ""20241104043758"", ""headline"": ""Tracking Yacktman Asset Management Portfolio - Q3 2024 Update"", ""summary"": ""Yacktman's 13F equity portfolio value decreased from $10.66B to $9.75B this quarter. Read more to see the portfolio's Q3, 2024 update.""}, {""date"": ""20241104201100"", ""headline"": ""Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare"", ""summary"": ""Inovalon Unveils New Research, Products, and Solutions to Tackle Healthcare\u2019s Most Complex ChallengesBOWIE, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inovalon, a leading provider of cloud-based software solutions empowering data-driven healthcare, welcomed industry trailblazers and visionary executives to the stage at Empower 2024, sparking meaningful conversations with leaders from every corner of healthcare. The annual summit, focused on the intersection of healthcare and technology, welcomed att""}, {""date"": ""20241104223300"", ""headline"": ""AI Robot Trader Dumped Microsoft, Amazon Stocks and Went Defensive. Here\u2019s What It Bought."", ""summary"": ""AI Robot Trader Dumped Microsoft, Amazon Stocks and Went Defensive. Here\u2019s What It Bought.""}, {""date"": ""20241104233502"", ""headline"": ""Is Johnson & Johnson (JNJ) the Best Pharma Stock to Buy Right Now?"", ""summary"": ""We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other pharma stocks. Healthcare takes the concept of \u2018defensive\u2019 further than almost any industry, encompassing many companies that provide patient care, engage [\u2026]""}, {""date"": ""20241105043100"", ""headline"": ""Johnson & Johnson stock rises Tuesday, still underperforms market"", ""summary"": ""Johnson & Johnson stock rises Tuesday, still underperforms market""}, {""date"": ""20241105064326"", ""headline"": ""J&J: positive results from post-marketing study"", ""summary"": ""J&J reports that Shockwave Medical, a subsidiary of Johnson & Johnson MedTech, has announced the 30-day results of a post-marketing study evaluating the safety and efficacy of the Shockwave Peripheral...""}, {""date"": ""20241105110020"", ""headline"": ""With 73% ownership of the shares, Johnson & Johnson (NYSE:JNJ) is heavily dominated by institutional owners"", ""summary"": ""Key Insights Institutions' substantial holdings in Johnson & Johnson implies that they have significant influence over...""}, {""date"": ""20241105140018"", ""headline"": ""Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""20241105210606"", ""headline"": ""AP Race Call: Republican Michael Rulli wins reelection to U.S. House in Ohio's 6th Congressional District"", ""summary"": ""Republican Rep. Michael Rulli won reelection to a U.S. House seat representing eastern Ohio on Tuesday. The former state senator's victory allows him to retain a seat he first won in June, during a...""}, {""date"": ""20241105234400"", ""headline"": ""Why most healthcare stocks are falling with Trump\u2019s win, with some exceptions"", ""summary"": ""Why most healthcare stocks are falling with Trump\u2019s win, with some exceptions""}, {""date"": ""20241106133557"", ""headline"": ""BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion"", ""summary"": ""BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential despite high R&D costs.""}, {""date"": ""20241106144555"", ""headline"": ""QLV: Better Low-Volume ETF Than Quality ETF"", ""summary"": ""FlexShares US Quality Low Volatility Index Fund ETF reduces volatility but lags in returns. See why QLV ETF beats competitors but trails quality-focused ETFs.""}, {""date"": ""20241106163000"", ""headline"": ""From Growth To Value: Building A Portfolio With Brett Ashcroft Green"", ""summary"": ""Why Brett Ashcroft Green is looking at Japanese stocks, big tech and ETFs offering\u00c2\u00a0growth and income.""}, {""date"": ""20241106163100"", ""headline"": ""Johnson & Johnson stock outperforms competitors despite losses on the day"", ""summary"": ""Johnson & Johnson stock outperforms competitors despite losses on the day""}, {""date"": ""20241107084900"", ""headline"": ""Band-Aid, Tylenol parent\u2019s sales miss the mark amid weakness in skin health"", ""summary"": ""Band-Aid, Tylenol parent\u2019s sales miss the mark amid weakness in skin health""}, {""date"": ""20241107085135"", ""headline"": ""Johnson & Johnson : MedTech Receives FDA Approval for the VARIPULSE\u2122 Pulsed Field Ablation Platform for the Treatment of Atrial Fibrillation"", ""summary"": ""Johnson & Johnson MedTech Receives FDA Approval for the VARIPULSE\u2122 Pulsed Field Ablation Platform for the Treatment of Atrial Fibrillation The VARIPULSE\u2122 Platform is the...""}, {""date"": ""20241107091519"", ""headline"": ""J&J: to present its rheumatology results"", ""summary"": ""Johnson & Johnson announces that 43 presentations, highlighting its rheumatology portfolio and pipeline, will be presented at the American College of Rheumatology 2024 Annual Meeting. These...""}, {""date"": ""20241107102404"", ""headline"": ""J&J: FDA approves Varipulse in atrial fibrillation"", ""summary"": ""Johnson & Johnson MedTech announces that the FDA has approved its Varipulse platform for the treatment of drug-resistant paroxysmal atrial fibrillation. Integrated with the CARTO 3 electro-anatomical...""}, {""date"": ""20241107113552"", ""headline"": ""J&J wins FDA approval for Varipulse PFA system"", ""summary"": ""J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.""}, {""date"": ""20241107161411"", ""headline"": ""QUS: Mixing Value, Quality And Volatility For An Average Outcome"", ""summary"": ""SPDR MSCI USA StrategicFactors ETF (QUS) combines quality, value, and low-volatility strategies in a large and mid-cap universe. Read the full ETF analysis here.""}, {""date"": ""20241107163100"", ""headline"": ""Johnson & Johnson stock underperforms Thursday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Thursday when compared to competitors""}, {""date"": ""20241107180000"", ""headline"": ""My Top 10 High Dividend Yield Companies For November 2024: 2 Yield More Than 8%"", ""summary"": ""Discover 10 high dividend yield companies worth investing in for November 2024. Click here to read what investors need to know.""}, {""date"": ""20241107194607"", ""headline"": ""FDA Greenlights J&J's Varipulse Device for Safer Atrial Fibrillation Treatment"", ""summary"": ""FDA approves Johnson & Johnson's Varipulse for targeted atrial fibrillation treatment, enhancing precision and safety""}, {""date"": ""20241108064627"", ""headline"": ""Johnson & Johnson advances leadership in rheumatic disease innovation With 43 abstracts at ACR 2024"", ""summary"": ""SPRING HOUSE - Johnson & Johnson announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology 2024...""}, {""date"": ""20241108091500"", ""headline"": ""Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever"", ""summary"": ""You'll also like these stocks for their track record of earnings growth.""}, {""date"": ""20241108102743"", ""headline"": ""Johnson & Johnson MedTech\u2019s VARIPULSE Platform receives FDA approval for AFib"", ""summary"": ""The platform works in conjunction with the CARTO 3 system, enhancing the safety of ablation procedures.""}, {""date"": ""20241108103612"", ""headline"": ""J&J: FDA & EMA applications for Darzalex Faspro in myeloma"", ""summary"": ""Johnson & Johnson announces that it has submitted applications to the FDA and EMA for a new indication for Darzalex Faspro in the United States and for the subcutaneous formulation Darzalex in the...""}, {""date"": ""20241108120000"", ""headline"": ""Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO\u00ae / DARZALEX\u00ae as subcutaneous monotherapy for high-risk smoldering multiple myeloma"", ""summary"": ""Johnson & Johnson (NYSE:JNJ) today announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of a new indication for DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) in the U.S. and DARZALEX\u00ae subcutaneous (SC) formulation in the European Union (EU). The applications are supported by data from the ongoing Phase 3 AQUILA study (NCT03301220) of DARZALEX FASPRO\u00ae as monotherapy for the treatment of adul""}, {""date"": ""20241108153842"", ""headline"": ""Why Johnson & Johnson (JNJ)\u2019s Legal Issues Could Wrap Up Quickly"", ""summary"": ""The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since then, the company has been dealing with litigation, trying its best to get away with it without having to pay much. The progress on the lawsuit is likely to be decided in [\u2026]""}, {""date"": ""20241109090000"", ""headline"": ""5 Relatively Secure And Cheap Dividend Stocks - November 2024: Yields Up To 9%"", ""summary"": ""Discover top dividend-paying stocks offering discounts, with yields ranging from 3.35% to 9%.""}, {""date"": ""20241110032710"", ""headline"": ""67 Aristocrats November Dividend Cornucopia Has 39 'Safer' And 2 Ideal Dogs"", ""summary"": ""Analysts forecast 12.5% to 20.12% net gains from the top-ten Aristocrat Dogs by November 2025. Read more to see my picks.""}, {""date"": ""20241110122616"", ""headline"": ""Cartesian Therapeutics: Uncertainty Remains"", ""summary"": ""Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed results for Descartes-08 in myasthenia gravis.""}]",{}
1,2024-11-10,153.0076904296875,2024-11-17,151.56097412109375,-0.009455186889828715,D1,"[{""date"": ""20241110032710"", ""headline"": ""67 Aristocrats November Dividend Cornucopia Has 39 'Safer' And 2 Ideal Dogs"", ""summary"": ""Analysts forecast 12.5% to 20.12% net gains from the top-ten Aristocrat Dogs by November 2025. Read more to see my picks.""}, {""date"": ""20241110122616"", ""headline"": ""Cartesian Therapeutics: Uncertainty Remains"", ""summary"": ""Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed results for Descartes-08 in myasthenia gravis.""}, {""date"": ""20241111080000"", ""headline"": ""Spravato is just the beginning in a new wave of depression meds"", ""summary"": ""Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.""}, {""date"": ""20241111103626"", ""headline"": ""Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO, DARZALEX as subcutaneous monotherapy for high-risk smoldering multiple myeloma"", ""summary"": ""RARITAN - Johnson & Johnson today announced the submission of regulatory applications to the U.S. Food and Drug Administration and European Medicines Agency seeking approval of a new indication for...""}, {""date"": ""20241111110121"", ""headline"": ""Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?"", ""summary"": ""It is hard to get excited after looking at Johnson & Johnson's (NYSE:JNJ) recent performance, when its stock has...""}, {""date"": ""20241111163100"", ""headline"": ""Johnson & Johnson stock outperforms competitors despite losses on the day"", ""summary"": ""Johnson & Johnson stock outperforms competitors despite losses on the day""}, {""date"": ""20241111210500"", ""headline"": ""Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sj\u00f6gren's disease"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy designation (BTD) for the treatment of adults living with moderate-to-severe Sj\u00f6gren's disease (SjD), a debilitating and chronic autoantibody disease with high prevalence, for which no approved advanced treatments are available.1,2,3,4 Nipocalimab is the only investigational therapy to secure this designation in SjD. This regulatory milestone is the second t""}, {""date"": ""20241112081711"", ""headline"": ""Johnson & Johnson : MedTech Receives IDE Approval for OTTAVA\u2122 Robotic Surgical System"", ""summary"": ""New Brunswick, NJ - November 12, 2024 - Johnson & Johnson MedTech, a global leader in cardiovascular, orthopaedic, surgery and vision solutions, today announced that the U.S. Food & Drug...""}, {""date"": ""20241112092338"", ""headline"": ""Johnson & Johnson - Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjogren's disease"", ""summary"": ""Spring House - Johnson & Johnson today announced that the U.S. Food and Drug Administration has granted nipocalimab Breakthrough Therapy designation for the treatment of adults living with...""}, {""date"": ""20241112100414"", ""headline"": ""J&J: FDA green light for robotic system trial"", ""summary"": ""Johnson & Johnson MedTech has announced that the FDA has approved the Investigational Device Exemption for its OTTAVA robotic surgical system, thereby authorizing the launch of clinical trials in the...""}, {""date"": ""20241112102009"", ""headline"": ""J&J: 'Breakthrough Therapy' from the FDA for nipocalimab"", ""summary"": ""Johnson & Johnson announces that the FDA has granted nipocalimab Breakthrough Therapy designation for the treatment of adults with moderate to severe Sj\u00f6gren's disease. Nipocalimab is the first...""}, {""date"": ""20241112102800"", ""headline"": ""3M, UnitedHealth share losses lead Dow's 115-point drop"", ""summary"": ""3M, UnitedHealth share losses lead Dow's 115-point drop""}, {""date"": ""20241112113900"", ""headline"": ""3M, Boeing share losses contribute to Dow's 234-point drop"", ""summary"": ""3M, Boeing share losses contribute to Dow's 234-point drop""}, {""date"": ""20241112114003"", ""headline"": ""J&J\u2019s Ottava surgical robot to begin clinical trial after FDA nod"", ""summary"": ""With FDA approval of an investigational device exemption, J&J\u2019s soft tissue robot moves a step closer to challenging Intuitive Surgical\u2019s da Vinci system.""}, {""date"": ""20241112163100"", ""headline"": ""Johnson & Johnson stock underperforms Tuesday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Tuesday when compared to competitors""}, {""date"": ""20241112200400"", ""headline"": ""J&J Sues U.S. Over Hospital Drug-Discounting Program"", ""summary"": ""The company filed a lawsuit asking for a federal court\u2019s permission to change when it gives lucrative drug discounts to hospitals.""}, {""date"": ""20241113070000"", ""headline"": ""TRex Bio raises $84M to compete in crowded immune drug field"", ""summary"": ""The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune system.""}, {""date"": ""20241113082857"", ""headline"": ""Q3 2024 Legend Biotech Corp Earnings Call"", ""summary"": ""Q3 2024 Legend Biotech Corp Earnings Call""}, {""date"": ""20241113083308"", ""headline"": ""J&J sues federal government for halting 340B rebate plan"", ""summary"": ""The New Jersey-based drugmaker is trying to get the courts\u2019 backing to pay hospitals rebates for two drugs in the 340B drug discount program, instead of offering upfront discounts.""}, {""date"": ""20241113091024"", ""headline"": ""Johnson & Johnson: Tracking Well Above The Industry"", ""summary"": ""Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating from financial writer. Read more here.""}, {""date"": ""20241113101743"", ""headline"": ""Johnson & Johnson MedTech Receives IDE Approval for OTTAVA Robotic Surgical System"", ""summary"": ""New Brunswick - Johnson & Johnson MedTech, a global leader in cardiovascular, orthopaedic, surgery and vision solutions, today announced that the U.S. Food & Drug Administration has approved the...""}, {""date"": ""20241113110800"", ""headline"": ""Texas Instruments and Other Overlooked Dividend Aristocrat Stocks"", ""summary"": ""Texas Instruments and Other Overlooked Dividend Aristocrat Stocks""}, {""date"": ""20241113163100"", ""headline"": ""Johnson & Johnson stock underperforms Wednesday when compared to competitors despite daily gains"", ""summary"": ""Johnson & Johnson stock underperforms Wednesday when compared to competitors despite daily gains""}, {""date"": ""20241113165817"", ""headline"": ""J&J MedTech wins IDE for Ottava to greenlight trials for surgical robot"", ""summary"": ""J&J MedTech is aiming to disrupt a robotic surgical market dominated by Intuitive\u2019s Da Vinci systems.""}, {""date"": ""20241113170041"", ""headline"": ""Why Johnson & Johnson, Invitation Homes And Extra Space Storage Are Winners For Passive Income"", ""summary"": ""Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Johnson & Johnson, Invitation Homes and Extra Space Storage have rewarded shareholders for decades and recently announced ...""}, {""date"": ""20241113184055"", ""headline"": ""Tracking Jeremy Grantham's GMO Capital Portfolio - Q3 2024 Update"", ""summary"": ""GMO\u00e2\u0080\u0099s 13F portfolio increased to $31.91B in Q3 2024. Click here to read more about the holdings and trades of GMO Capital Portfolio.""}, {""date"": ""20241114085311"", ""headline"": ""Johnson & Johnson : MedTech Announces Strategic Agreement with Responsive Arthroscopy to Expand Sports Soft Tissue Solutions"", ""summary"": ""WEST CHESTER, Penn. - November 14, 2024 - Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, announced today an exclusive commercial distribution agreement in the...""}, {""date"": ""20241114094824"", ""headline"": ""J&J: distribution agreement with Responsive Arthroscopy"", ""summary"": ""J&J announces that its 'MedTech' division has reached an exclusive commercial distribution agreement in the USA with Responsive Arthroscopy, a company specializing in soft tissue repair solutions for...""}, {""date"": ""20241114110313"", ""headline"": ""J&J: Phase 2 endpoint met in Sj\u00f6gren's disease"", ""summary"": ""Johnson & Johnson announced on Thursday that a Phase 2 study had met its primary endpoint in the treatment of Sj\u00f6gren's syndrome, an autoimmune disease characterized by dry mucous membranes.The...""}, {""date"": ""20241114150000"", ""headline"": ""Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sj\u00f6gren's disease study"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction by over 77% following treatment with investigational nipocalimab in adult patients with moderate-to-severe Sj\u00f6gren's disease (SjD). These data were included in a plenary session presentation (Abstract #2527) and two posters (Abstracts #1427 and #2294) and are among the Company's 43 oral and poster pr""}, {""date"": ""20241114150000"", ""headline"": ""How To Build A $100,000 Dividend Portfolio: A Strategic Guide To Balance Income And Growth"", ""summary"": ""The portfolio effectively integrates the generation of dividend income with the potential for dividend growth. Read more to see my recommendations.""}, {""date"": ""20241114163015"", ""headline"": ""Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?"", ""summary"": ""Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""20241114163100"", ""headline"": ""Johnson & Johnson stock underperforms Thursday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Thursday when compared to competitors""}, {""date"": ""20241115022423"", ""headline"": ""Intuitive Surgical: The Price For Its Excellence Is Too High"", ""summary"": ""Is Intuitive Surgical a buy or hold? Find out why the leading robotic surgery company may be overvalued and whether it's worth waiting for a better entry.""}, {""date"": ""20241115064500"", ""headline"": ""Fidelity Value Discovery Fund Q3 2024 Review"", ""summary"": ""On the positive side, the fund benefited from favorable stock picking in industrials, health care and information technology, as well as an underweight in the last of these three sectors.""}, {""date"": ""20241115073000"", ""headline"": ""2 Of The Cheapest, High-Quality Dividend Stocks On The Market"", ""summary"": ""Read an analysis on two dividend stocks with growth potential and inflation protection, designed to thrive in today's market for stable income.""}, {""date"": ""20241115095738"", ""headline"": ""How To Invest $100,000 In Large Cap Stocks: A Tax-Efficient Advisor-Less Strategy"", ""summary"": ""This DIY market index strategy blends large-cap stocks and ETFs, plus tax loss harvesting. Read how you can save on fees and manage your own portfolio.""}, {""date"": ""20241115110007"", ""headline"": ""Johnson & Johnson : CHMP recommends RYBREVANT\u00ae\u25bc (amivantamab) in combination with LAZCLUZE\u00ae\u25bc (lazertinib) for the first line treatment of patients with EGFR mutated advanced non small cell lung cancer"", ""summary"": ""Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the Marketing...""}, {""date"": ""20241115115158"", ""headline"": ""J&J\u2019s nipocalimab shows promise in Phase II Sj\u00f6gren\u2019s disease trial"", ""summary"": ""The trial met its primary endpoint, a change in the baseline ClinESSDAI score at week 24.""}, {""date"": ""20241115122335"", ""headline"": ""Johnson & Johnson MedTech announces partnership\u00a0for soft tissue solutions"", ""summary"": ""The collaboration will provide advanced soft tissue repair solutions for shoulder, foot and ankle procedures.""}, {""date"": ""20241115140213"", ""headline"": ""Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program"", ""summary"": ""Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facilities.""}, {""date"": ""20241115141525"", ""headline"": ""Johnson & Johnson (JNJ) Guggenheim Global Healthcare Conference (Transcript)"", ""summary"": ""Johnson &amp; Johnson (NYSE:JNJ) Guggenheim Global Healthcare Conference November 12, 2024 10:30 AM ETCompany ParticipantsBiljana Naumovic - Worldwide VP,...""}, {""date"": ""20241115163100"", ""headline"": ""Johnson & Johnson stock underperforms Friday when compared to competitors despite daily gains"", ""summary"": ""Johnson & Johnson stock underperforms Friday when compared to competitors despite daily gains""}, {""date"": ""20241116055238"", ""headline"": ""Wolfe Research Initiates Coverage of Johnson & Johnson (JNJ) with Outperform Recommendation"", ""summary"": """"}, {""date"": ""20241117114714"", ""headline"": ""Bristol-Myers Squibb: Buy This Bargain Before It's Gone"", ""summary"": ""Discover why Bristol-Myers Squibb's stock price has risen 25% in six months and why it's rated a 'Buy' with a 4% dividend yield.""}]",{}
2,2024-11-17,151.56097412109375,2024-11-24,152.7124481201172,0.0075974307086692505,U1,"[{""date"": ""20240126151000"", ""headline"": ""Layoffs in 2024: A List of Companies Cutting Jobs This Year"", ""summary"": ""Google said it planned to lay off more employees this year but at a smaller scale than in 2023, when it cut more than 12,000 workers as part of large trims across the tech industry.  Chief Executive  Sundar Pichai  told employees in a Jan. 17 memo the company would have to make tough choices as it funded investments in areas like artificial intelligence.""}, {""date"": ""20241117114714"", ""headline"": ""Bristol-Myers Squibb: Buy This Bargain Before It's Gone"", ""summary"": ""Discover why Bristol-Myers Squibb's stock price has risen 25% in six months and why it's rated a 'Buy' with a 4% dividend yield.""}, {""date"": ""20241118055518"", ""headline"": ""J&J: positive CHMP opinion for Lazcluze in lung cancer"", ""summary"": ""Janssen-Cilag International NV, a subsidiary of Johnson & Johnson, has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing...""}, {""date"": ""20241118070629"", ""headline"": ""Johnson & Johnson - CHMP recommends RYBREVANT in combination with LAZCLUZE for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer"", ""summary"": ""BEERSE, BELGIUM - Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has...""}, {""date"": ""20241118102800"", ""headline"": ""Eli Lilly follows J&J in suing Biden administration over 340B rebates"", ""summary"": ""Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead of giving them upfront discounts on 340B drugs.""}, {""date"": ""20241118124200"", ""headline"": ""CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC"", ""summary"": ""The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.""}, {""date"": ""20241118160212"", ""headline"": ""Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript)"", ""summary"": ""Johnson &amp; Johnson (NYSE:JNJ) Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ETCompany ParticipantsMichael Bodner - Group President, Heart...""}, {""date"": ""20241118162050"", ""headline"": ""Johnson & Johnson appoints CIO to lead business technology strategy"", ""summary"": ""Chris Della Rocca previously served the company as CIO overseeing technical operations and risk.""}, {""date"": ""20241118163100"", ""headline"": ""Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains"", ""summary"": ""Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains""}, {""date"": ""20241118165028"", ""headline"": ""Johnson & Johnson : to Participate in the Stifel 2024 Healthcare Conference Press Release"", ""summary"": ""Media contact: Investor contact: ...""}, {""date"": ""20241118170827"", ""headline"": ""Globus Medical Stock: Re-Rated After A Solid Year"", ""summary"": ""Globus Medical saw strong growth from the NuVasive deal. Read why GMED stock\u00e2\u0080\u0099s $81 valuation suggests the easy gains may be over for now.""}, {""date"": ""20241118182748"", ""headline"": ""How Robert F. Kennedy Jr. could impact the healthcare sector as secretary of health"", ""summary"": ""Robert F. Kennedy Jr.'s nomination to lead HHS is causing cautious concern among investors. Here's which companies and stocks could be impacted, as well as which policies are in line for disruption.""}, {""date"": ""20241118203546"", ""headline"": ""Tracking Tweedy Browne Portfolio - Q3 2024 Update"", ""summary"": ""Tweedy Browne's 13F portfolio value drops to $2.10B with reductions in top positions like Berkshire Hathaway and Alphabet. Read an update on the portfolio here.""}, {""date"": ""20241118213000"", ""headline"": ""Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of icotrokinra (JNJ-2113), the first targeted oral peptide that selectively blocks the IL-23 receptor, in adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO). The Phase 3 study met its co-primary endpoints of Psoriasis Area and Severity Index (PASI) 90b and Investigator's Global Assessment (IGA) of 0/1c response at week 16 a""}, {""date"": ""20241119051000"", ""headline"": ""Fidelity Select Health Care Portfolio Q3 2024 Fund Review"", ""summary"": ""For Q3 2024, the Fidelity Select Health Care Portfolio fund gained 9.48%, outperforming the MSCI sector index. Click here to read the full commentary.""}, {""date"": ""20241119052527"", ""headline"": ""J&J: positive results for icotrokinra in psoriasis"", ""summary"": ""Johnson & Johnson announces positive results from a Phase 3 study of icotrokinra for patients aged 12 and over with moderate to severe plaque psoriasis. The study met its primary objectives, with...""}, {""date"": ""20241119091500"", ""headline"": ""IXJ: Healthcare Sector\u00a0Dashboard For November"", ""summary"": ""November dashboard shows the healthcare sector is overvalued by 18% relative to 11-yr averages; pharma/biotech and healthcare equipment, the most overpriced.""}, {""date"": ""20241119094500"", ""headline"": ""Home Depot, Walt Disney share losses lead Dow's 325-point fall"", ""summary"": ""Home Depot, Walt Disney share losses lead Dow's 325-point fall""}, {""date"": ""20241119102203"", ""headline"": ""Johnson & Johnson reports topline outcomes from trial of icotrokinra for psoriasis"", ""summary"": ""The trial met its co-primary endpoints at week 16, with skin clearance observed compared to placebo.""}, {""date"": ""20241119104600"", ""headline"": ""Walt Disney, Sherwin-Williams Co. share losses lead Dow's nearly 200-point fall"", ""summary"": ""Walt Disney, Sherwin-Williams Co. share losses lead Dow's nearly 200-point fall""}, {""date"": ""20241119105046"", ""headline"": ""Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive"", ""summary"": ""Johnson & Johnson faces uncertainty with speculation about RFK Jr. at HHS. Learn why JNJ stock remains a buy despite political risks and soft trends.""}, {""date"": ""20241119112312"", ""headline"": ""J&J: to present its advances in hematology"", ""summary"": ""Johnson & Johnson will present more than 90 abstracts covering data from its portfolio and sib pipeline in the treatment of blood cancers at the 66th annual meeting of the American Society of...""}, {""date"": ""20241119112400"", ""headline"": ""J&J pill clears skin in two late-stage psoriasis studies"", ""summary"": ""The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down the inflammation involved in psoriasis and other immune diseases.""}, {""date"": ""20241119123445"", ""headline"": ""How I Repurposed My Late Father's Trust Account"", ""summary"": ""I restructured my father's Trust for better diversification and risk reduction. See why I reduced Health Care and Consumer stocks and shifted to new sectors.""}, {""date"": ""20241119140017"", ""headline"": ""Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""20241119163100"", ""headline"": ""Johnson & Johnson stock underperforms Tuesday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Tuesday when compared to competitors""}, {""date"": ""20241119180000"", ""headline"": ""If I Could Only Buy 2 High Dividend Yield Companies In November 2024: Both Yield Above 6%"", ""summary"": ""I have selected Pfizer and Verizon as my top two high dividend yield companies to invest in for November 2024. Click here to read why.""}, {""date"": ""20241120070000"", ""headline"": ""BlackRock Advantage Global Fund Q3 2024 Commentary"", ""summary"": ""The fund posted returns of 5.38% (Institutional shares) and 5.32% (Investor A shares, without sales charge) for the third quarter of 2024.""}, {""date"": ""20241120081000"", ""headline"": ""My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys"", ""summary"": ""Investment activity in October focused on Business Development Companies. Check out my portfolio, my main picks, and my target for 2024.""}, {""date"": ""20241120090800"", ""headline"": ""XLV: Healthcare Stocks In Critical Condition (Rating Downgrade)"", ""summary"": ""We advise selling healthcare stocks due to political uncertainty and unfavorable market conditions, prioritizing low-risk investments. See more on XLV ETF here.""}, {""date"": ""20241120110832"", ""headline"": ""Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting"", ""summary"": ""RARITAN - Johnson & Johnson announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society...""}, {""date"": ""20241120140900"", ""headline"": ""Dr. Oz Goes From TV to the Most Important Job in Healthcare. Here\u2019s What CMS Actually Does."", ""summary"": ""Dr. Oz Goes From TV to the Most Important Job in Healthcare. Here\u2019s What CMS Actually Does.""}, {""date"": ""20241120160525"", ""headline"": ""Of 63 Fortune 500 Industry Leaders, 57 Pay Dividends, 38 Are Cash Rich And 1 Is A Buy"", ""summary"": ""Top F500IL dividend stocks like AT&T, Altria, and Energy Transfer promise gains. Read why Energy Transfer stands as a safer choice.""}, {""date"": ""20241120163100"", ""headline"": ""Johnson & Johnson stock underperforms Wednesday when compared to competitors despite daily gains"", ""summary"": ""Johnson & Johnson stock underperforms Wednesday when compared to competitors despite daily gains""}, {""date"": ""20241120195209"", ""headline"": ""Update: Market Chatter: Johnson & Johnson, Merck Cut Jobs in China"", ""summary"": ""Update: Market Chatter: Johnson & Johnson, Merck Cut Jobs in China""}, {""date"": ""20241121143000"", ""headline"": ""Franklin Income Fund Q3 2024 Commentary"", ""summary"": ""Franklin Income Fund underperformed its benchmark for the quarter ended September 30, 2024, while it outpaced the gain of the S&P 500 Index. Read more here.""}, {""date"": ""20241121160117"", ""headline"": ""Hundreds of women in UK sue Johnson & Johnson over link between talc and cancer"", ""summary"": ""Copyright \u00a9 BusinessAMBE 2023Key takeawaysHundreds of women in the United Kingdom are taking legal action against Johnson & Johnson on suspicion of a link between talc products and cancer.The...""}, {""date"": ""20241121162604"", ""headline"": ""Eli Lilly Stock: Unexpected Developments (Rating Downgrade)"", ""summary"": ""Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.""}, {""date"": ""20241121163100"", ""headline"": ""Johnson & Johnson stock outperforms competitors on strong trading day"", ""summary"": ""Johnson & Johnson stock outperforms competitors on strong trading day""}, {""date"": ""20241121210000"", ""headline"": ""Health Canada Authorizes CARVYKTI\u00ae (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI\u00ae (ciltacabtagene autoleucel) for the treatment of adult patients with multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.1 With this approval, CARVYKTI\u00ae becomes the first and only B-cell Maturation Antigen (BCMA)-targeted therapy approved for the treatment o""}, {""date"": ""20241122051007"", ""headline"": ""Lessons From Recent Decisions On Earnout Disputes"", ""summary"": ""Acquisition agreements sometimes include earnouts that provide for a portion of the purchase price to be payable only upon the achievement of specified milestones after the transaction closes. It is...""}, {""date"": ""20241122071500"", ""headline"": ""3 Dividend Kings So You Can Sleep Well At Night"", ""summary"": ""Discover why Dividend Kings like Coca-Cola, Johnson & Johnson, and Walmart are top long-term investments for their consistent growth and strong yields.""}, {""date"": ""20241122110917"", ""headline"": ""J&J Sues HRSA Over Agency's Challenge Of Its Rebate Model"", ""summary"": ""On November 12, Johnson & Johnson filed suit against the Health Resources and Services Administration in D.C. federal district court, arguing that the 340B statute explicitly provides flexibility...""}, {""date"": ""20241122121706"", ""headline"": ""Johnson & Johnson (NYSE:JNJ) Stock Goes Ex-Dividend In Just Three Days"", ""summary"": ""Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Johnson...""}, {""date"": ""20241122130000"", ""headline"": ""Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA\u00ae (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a subcutaneous (SC) induction regimen of TREMFYA\u00ae (guselkumab) for the treatment of adults with moderately to severely active UC. The filing is supported by data from the Phase 3 ASTRO study of TREMFYA\u00ae SC induction therapy in adults with UC and builds upon the recent U.S. approval of TREMFYA\u00ae in this indication.""}, {""date"": ""20241122151043"", ""headline"": ""AbbVie: Upgrading To 'Strong Buy' After Pullback"", ""summary"": ""AbbVie\u00e2\u0080\u0099s high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.""}, {""date"": ""20241122160805"", ""headline"": ""Health Canada issues NOC to J&J\u2019s CARVYKTI for multiple myeloma"", ""summary"": ""The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.""}, {""date"": ""20241122163100"", ""headline"": ""Johnson & Johnson stock underperforms Friday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Friday when compared to competitors""}, {""date"": ""20241122163900"", ""headline"": ""Sanofi Plans to Change Hospital Drug-Discount Program"", ""summary"": ""The drugmaker looks to rein in how it gives discounts in a federal program designed to help hospitals that serve low-income and uninsured patients.""}, {""date"": ""20241122170516"", ""headline"": ""Medtronic acquires Fortimedix Surgical to boost surgical portfolio"", ""summary"": ""Fortimedix Surgical\u2019s portfolio consists of articulating instruments for endoscopic, robotic, and minimally invasive surgeries.""}, {""date"": ""20241122172551"", ""headline"": ""J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis"", ""summary"": ""The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at week 12.""}, {""date"": ""20241123004924"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of November 24"", ""summary"": ""Stay informed on dividend activity with a weekly summary for Dividend Champions, Contenders, and Challengers, including changes and upcoming dates.""}, {""date"": ""20241123090200"", ""headline"": ""2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade"", ""summary"": ""If you have any faith in economic indicators, right now seems like a terrible time to buy stocks.  A long bull market has pushed the major market indices up to record highs.  As a result, the S&P 500's cyclically adjusted price-to-earnings ratio, or CAPE ratio, recently shot up past 35 for the third time in more than 150 years.""}, {""date"": ""20241123103600"", ""headline"": ""2 Unstoppable Dividend Stocks to Buy Now With $500"", ""summary"": ""Whether you prefer growth stocks, value stocks, dividend stocks, or a mixture of investments in your portfolio, price should only be one factor you consider when determining which businesses to add.  Dividends can be a great way to increase your returns with time while giving you extra capital to reinvest or keep in your portfolio.  If you're looking for two top dividend stocks to consider for your portfolio and have $500 available to invest, read on.""}, {""date"": ""20241123110000"", ""headline"": ""Dell, Autodesk, And CrowdStrike Headline Earnings Reports In Holiday-Shortened Week"", ""summary"": ""Stay ahead of the market with Seeking Alpha's Wall Street Week Ahead newsletter, previewing key events like earnings reports, IPOs, and economic indicators.""}, {""date"": ""20241123122000"", ""headline"": ""3 Dividend Stocks That Are Screaming Buys in November"", ""summary"": ""Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.""}, {""date"": ""20241123151611"", ""headline"": ""Hedge Funds Bet Big On Johnson & Johnson (JNJ): Top Healthcare Stock to Watch"", ""summary"": ""We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other most promising healthcare stocks according to hedge funds. The Healthcare Sector: Growth, Innovation, and the Impact of AI The healthcare sector [\u2026]""}]",{}
3,2024-11-24,152.7124481201172,2024-12-01,153.779052734375,0.006984398635393907,U1,"[{""date"": ""20241125140800"", ""headline"": ""J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC"", ""summary"": ""If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.""}, {""date"": ""20241125163100"", ""headline"": ""Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains"", ""summary"": ""Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains""}, {""date"": ""20241126062500"", ""headline"": ""Invesco Equity And Income Fund Q3 2024 Commentary"", ""summary"": ""The fund holds high-grade bonds and convertible securities as a source of income and to help provide a measure of stability in volatile markets.""}, {""date"": ""20241126081725"", ""headline"": ""Is Johnson & Johnson (JNJ) the Best Dividend Aristocrat Stock To Buy Right Now?"", ""summary"": ""We recently compiled a list of the 10 Best Dividend Aristocrat Stocks To Buy Right Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other dividend aristocrat stocks. Investors usually buy stocks with the expectation that their value will increase as the company grows more [\u2026]""}, {""date"": ""20241126090300"", ""headline"": ""Sanofi joins J&J, Eli Lilly in proposing 340B rebate model"", ""summary"": ""Sanofi plans to phase in its own rebate model for 25 drugs \u2014 including anti-inflammatory injectable Dupixent, one of the top 10 drugs in global sales \u2014 early next year. It\u2019s unclear how regulators will react.""}, {""date"": ""20241126102714"", ""headline"": ""Johnson & Johnson - After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists"", ""summary"": ""Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That's why they joined Johnson & Johnson's That's...""}, {""date"": ""20241126140032"", ""headline"": ""Investors in Johnson & Johnson (NYSE:JNJ) have seen decent returns of 30% over the past five years"", ""summary"": ""The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...""}, {""date"": ""20241126170012"", ""headline"": ""How To Put $100 In Your Retirement Fund Each Month With Johnson & Johnson"", ""summary"": ""Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures and sells various products in the health care field worldwide. It will report its Q4 2024 earnings on Jan. 22, 2025. Wall Street analysts expect the company to post an EPS of $2.29, ...""}, {""date"": ""20241126180000"", ""headline"": ""Strategic ETF Allocations: Enhancing Income, Diversification, And Reducing Risks In Your Dividend Portfolio"", ""summary"": ""I added shares of Schwab U.S. Dividend Equity ETF and the Cohen & Steers Quality Income Realty Fund to The Dividend Income Accelerator Portfolio. Find out why.""}, {""date"": ""20241126200000"", ""headline"": ""Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study"", ""summary"": ""MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.""}, {""date"": ""20241127054000"", ""headline"": ""Invesco Dividend Income Fund Q3 2024 Commentary"", ""summary"": ""The Invesco Dividend Income Fund delivered a solid positive return for the quarter but underperformed the Russell 1000 Value Index. Click here to read the full commentary. ""}, {""date"": ""20241127060000"", ""headline"": ""Invesco Growth And Income Fund Q3 2024 Commentary"", ""summary"": ""Stock selection in the information technology, financials, consumer discretionary and communication services sectors drove the fund\u00e2\u0080\u0099s underperformance.""}, {""date"": ""20241127071300"", ""headline"": ""Kenvue: Lots Of Potential, But Short-Term Upside May Be Tapped Out (Rating Downgrade)"", ""summary"": ""Higher interest rates and economic challenges in China continue to weigh on Kenvue's performance. Read why I am downgrading KVUE stock to a Hold.""}, {""date"": ""20241127100500"", ""headline"": ""Invesco Diversified Dividend Fund Q3 2024 Commentary"", ""summary"": ""Invesco Diversified Dividend Fund is balanced across sectors and industries, with a focus on long-term growth areas and companies with sustainable free cash flow and healthy balance sheets.""}, {""date"": ""20241128124500"", ""headline"": ""2 Excellent Healthcare Stocks to Hold Through the Next Decade"", ""summary"": ""Although excellent medical care is always in high demand, the healthcare sector continuously evolves.  Let's consider two that specialize in developing medical devices: DexCom (NASDAQ: DXCM) and Intuitive Surgical (NASDAQ: ISRG).  DexCom has encountered some issues lately.""}, {""date"": ""20241128150000"", ""headline"": ""How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding"", ""summary"": ""Johnson & Johnson offers an effective combination of dividend income and dividend growth. Check out my portfolio with JNJ stock as the largest proportion.""}, {""date"": ""20241129005000"", ""headline"": ""Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary"", ""summary"": ""The Janus Henderson Global Life Sciences Diversified ADR Managed Account\u00c2\u00a0Portfolio returned 5.74% (gross) for Q3 2024. Click here to read the full commentary.""}, {""date"": ""20241129073000"", ""headline"": ""Forget Big Tech - I'll Take Dividend Stalwarts Any Day"", ""summary"": ""Discover why dividend stocks in VYM and SCHD ETFs offer a safer alternative to tech investments, with strong cash flow, low risks, and reliable growth. Read what investors need to know.""}, {""date"": ""20241129163100"", ""headline"": ""Johnson & Johnson stock underperforms Friday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Friday when compared to competitors""}, {""date"": ""20241130090000"", ""headline"": ""The Dividend Aristocrats Ranked By Quality Scores: November 2024"", ""summary"": ""Financial writer ranks S&P 500 Dividend Aristocrats by quality scores, categorizes undervalued/overvalued stocks, provides detailed analysis for informed...""}, {""date"": ""20241201095500"", ""headline"": ""These 3 Dividend-Focused Vanguard ETFs Are Up 14% to 31% in 2024. Here's the Best One to Buy Now."", ""summary"": ""Investment management company Vanguard offers more than 60 equity-focused exchange-traded funds (ETFs) that focus on various investment styles and themes -- all while charging expense ratios as low as 0.03% to as high as 0.22%.  While plenty of dividend-focused Vanguard funds are great for generating passive income, not all of them have produced impressive gains this year.  Here's a closer look at three high-yield Vanguard ETFs that can continue rewarding patient investors.""}, {""date"": ""20241201105200"", ""headline"": ""3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later"", ""summary"": ""You don't have to be an income investor to like dividends.  Many billionaires who definitely don't need income still have dividend stocks in their portfolios.  Which dividend stocks are great picks right now?""}]",{}
4,2024-12-01,153.779052734375,2024-12-08,148.1243133544922,-0.036771844274852805,D4,"[{""date"": ""20241201095500"", ""headline"": ""These 3 Dividend-Focused Vanguard ETFs Are Up 14% to 31% in 2024. Here's the Best One to Buy Now."", ""summary"": ""Investment management company Vanguard offers more than 60 equity-focused exchange-traded funds (ETFs) that focus on various investment styles and themes -- all while charging expense ratios as low as 0.03% to as high as 0.22%.  While plenty of dividend-focused Vanguard funds are great for generating passive income, not all of them have produced impressive gains this year.  Here's a closer look at three high-yield Vanguard ETFs that can continue rewarding patient investors.""}, {""date"": ""20241201105200"", ""headline"": ""3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later"", ""summary"": ""You don't have to be an income investor to like dividends.  Many billionaires who definitely don't need income still have dividend stocks in their portfolios.  Which dividend stocks are great picks right now?""}, {""date"": ""20241202034635"", ""headline"": ""Tracking Ray Dalio's Bridgewater Associates 13F Portfolio - Q3 2024 Update"", ""summary"": ""Bridgewater Associates' 13F portfolio decreased to ~$17.66B. Read more to see the portfolio's Q3, 2024 update.""}, {""date"": ""20241202080110"", ""headline"": ""Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA\u00ae (guselkumab)"", ""summary"": ""Applications filed for TREMFYA\u00ae to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis\u00a0 SPRING HOUSE, Pa., Dec. 2, 2024 /PRNewswire/ -- Johnson & Johnson...""}, {""date"": ""20241202091616"", ""headline"": ""J&J: FDA green light for MemoryGel breast implants"", ""summary"": ""J&J announces that Mentor Worldwide LLC, the world's leading brand in breast aesthetics and a subsidiary of Johnson & Johnson MedTech, has received FDA approval for its MemoryGel Enhance breast...""}, {""date"": ""20241202093514"", ""headline"": ""J&J: applies to the FDA for Tremfya in pediatrics"", ""summary"": ""Johnson & Johnson announces that it has submitted two supplemental Biologics License Applications to the FDA for approval of Tremfya in children aged 6 and over with moderate to severe plaque...""}, {""date"": ""20241202112400"", ""headline"": ""J&J appoints Shawn Millerick to lead vision care unit in the Americas"", ""summary"": ""Millerick, who spent time at Abbott and Alcon, is responsible for defining strategy and driving growth at a J&J business that sells products including Acuvue contact lenses.""}, {""date"": ""20241202122549"", ""headline"": ""Why Is Johnson & Johnson (JNJ) Among the Stocks Ray Dalio\u2019s Bridgewater Is Crazy About?"", ""summary"": ""We recently compiled a list of the Billionaire Ray Dalio\u2019s Bridgewater Is Crazy About These 15 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other stocks Ray Dalio\u2019s Bridgewater is crazy about. Ray Dalio, a seasoned global macro investor with over 50 years of [\u2026]""}, {""date"": ""20241202163100"", ""headline"": ""Johnson & Johnson stock underperforms Monday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Monday when compared to competitors""}, {""date"": ""20241202164113"", ""headline"": ""Johnson & Johnson : MENTOR\u2122 MemoryGel\u2122 Enhance Breast Implant Receives FDA Approval for Largest Size Breast Implants for Reconstruction"", ""summary"": ""Media contact: Investor contact: Tracy Menkowski ...""}, {""date"": ""20241202182905"", ""headline"": ""Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know"", ""summary"": ""Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""20241202195200"", ""headline"": ""Why Dividend Aristocrats Like Walmart, ADP, and AbbVie Are Set to Outperform"", ""summary"": ""With Treasury yields coming down, more income-hungry investors could turn their attention to dividends, according to a new report by Wolfe Research.""}, {""date"": ""20241203071010"", ""headline"": ""PBM Contracting And Administration: What Are The Rules Of The Road For Self-Insured Employees?"", ""summary"": ""In February 2024, a group representing the Johnson & Johnson Group Health Plan and its component plans sued Johnson & Johnson and The Pension & Benefits Committee of Johnson and Johnson over the...""}, {""date"": ""20241203103735"", ""headline"": ""Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA"", ""summary"": ""SPRING HOUSE - Johnson & Johnson today announced the submission of two supplemental Biologics License Applications to the U.S. Food and Drug Administration seeking approval of TREMFYA for the...""}, {""date"": ""20241203111958"", ""headline"": ""J&J\u2019s sBLAs seek FDA approval of TREMFYA for paediatric conditions"", ""summary"": ""The submission for treating paediatric plaque psoriasis is supported by outcomes from the Phase III PROTOSTAR study in children.""}, {""date"": ""20241203120021"", ""headline"": ""37% Of This Johnson & Johnson Insider's Holdings Were Sold"", ""summary"": ""Viewing insider transactions for Johnson & Johnson's ( NYSE:JNJ ) over the last year, we see that insiders were net...""}, {""date"": ""20241203135800"", ""headline"": ""J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids"", ""summary"": ""J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients""}, {""date"": ""20241203140045"", ""headline"": ""You Buy Products From These Dual Dividend Aristocrat and Dividend King Stocks Every Day \u2013 Why Not Earn Passive Income On Their Shares?"", ""summary"": ""Have you ever looked high and low for something without realizing it was right in front of you the entire time? It's a surprisingly common situation, especially for passive income investors seeking reliable dividend stocks. You may consider investing ...""}, {""date"": ""20241203141854"", ""headline"": ""MeiraGTx Holdings: Behind The Recent Rally"", ""summary"": ""MeiraGTx Holdings plc sees a surge in stock after positive Parkinson's disease data and strategic partnerships, showing growth potential. Click for my MGTX update.""}, {""date"": ""20241204080000"", ""headline"": ""The big rebrand: Why these 4 biopharmas changed their name this year"", ""summary"": ""Four companies that refreshed their mission and public persona with a new look.""}, {""date"": ""20241204130507"", ""headline"": ""Why Is Johnson & Johnson (JNJ) Among the Dividend Kings You Should Consider?"", ""summary"": ""We recently compiled a list of the Dividend Kings List: Top 15. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other dividend kings you should know about. Dividend Kings are a distinguished group of companies that have achieved at least 50 consecutive years of dividend [\u2026]""}, {""date"": ""20241204163100"", ""headline"": ""Johnson & Johnson stock underperforms Wednesday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Wednesday when compared to competitors""}, {""date"": ""20241204173718"", ""headline"": ""Dow 30 December Dogs Show 28 Pay Dividends And 1 \""Safer\"" Buy"", ""summary"": ""While most of this collection of Dow Industrials is too pricey and reveals only skinny dividends, one of the ten lowest priced Dogs of the Dow is ready to buy. Read on to find out which one.""}, {""date"": ""20241204223000"", ""headline"": ""Columbia Dividend Income Fund Q3 2024 Commentary"", ""summary"": ""Institutional Class shares of Columbia Dividend Income Fund returned 8.12% for the \nquarter ending September 30, 2024. Click here to read the full commentary. ""}, {""date"": ""20241204224504"", ""headline"": ""Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade"", ""summary"": ""In the most recent trading session, Johnson & Johnson (JNJ) closed at $150.47, indicating a -1.24% shift from the previous trading day.""}, {""date"": ""20241205001500"", ""headline"": ""Columbia Dividend Opportunity Fund Q3 2024 Commentary"", ""summary"": ""Institutional Class shares of Columbia Dividend Opportunity Fund returned 9.51% for the \nthird quarter. Click here to read the full commentary. \n""}, {""date"": ""20241205090804"", ""headline"": ""Johnson & Johnson : MedTech Joins Experts to Define and Classify Surgical Site Outcomes"", ""summary"": ""Healthcare experts call for consistent definitions in the assessment, reporting, and monitoring of surgical wounds A standardized...""}, {""date"": ""20241205104009"", ""headline"": ""J&J: classification system for surgical complications"", ""summary"": ""Johnson & Johnson MedTech has announced a partnership with leading surgeons to develop a standardized classification system for surgical complications . The project aims to better assess and report...""}, {""date"": ""20241205141442"", ""headline"": ""Legend Biotech: The Story Brightens"", ""summary"": ""Legend Biotech\u00e2\u0080\u0099s Carvykti therapy is driving growth, supported by strong financials. Discover why LEGN stock has a bullish outlook from analysts.""}, {""date"": ""20241205163100"", ""headline"": ""Johnson & Johnson stock underperforms Thursday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Thursday when compared to competitors""}, {""date"": ""20241205214000"", ""headline"": ""Top Analyst Reports for Home Depot, Johnson & Johnson & Salesforce"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Johnson & Johnson (JNJ) and Salesforce, Inc. (CRM), as well as two micro-cap stocks, Preformed Line Products Company (PLPC) and Cooper-Standard Holdings Inc. (CPS).""}, {""date"": ""20241206100000"", ""headline"": ""The Zacks Analyst Blog Highlights Home Depot, Johnson & Johnson, Salesforce, Preformed Line and Cooper-Standard"", ""summary"": ""Home Depot, Johnson & Johnson, Salesforce, Preformed Line and Cooper-Standard are included in this Analyst Blog.""}, {""date"": ""20241206135052"", ""headline"": ""Johnson & Johnson Is A Better Dividend Stock Than Amgen In Our View"", ""summary"": ""Market concerns push Johnson & Johnson and Amgen Inc. stocks. JNJ a strong buy with timeless dividends advice, while AMGN is downgraded. Click for more.""}, {""date"": ""20241206163100"", ""headline"": ""Johnson & Johnson stock outperforms competitors despite losses on the day"", ""summary"": ""Johnson & Johnson stock outperforms competitors despite losses on the day""}, {""date"": ""20241207003735"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 8"", ""summary"": ""Stay updated on dividend activity with a weekly summary for Dividend Champions, Contenders, and Challengers, including changes and upcoming dates.""}, {""date"": ""20241207070000"", ""headline"": ""12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style"", ""summary"": ""Discover how low-volatility, high-yield Dividend Aristocrats can provide a stable alternative to the S&P in 2025. Click for more.""}, {""date"": ""20241207090000"", ""headline"": ""5 Relatively Secure And Cheap Dividend Stocks For December 2024: Yields Up To 9%"", ""summary"": ""Discover 15 dividend-paying stocks to consider for your portfolio, including safe picks with discounts and yields ranging from 3.28% to 9%. Click for the picks.""}, {""date"": ""20241207175602"", ""headline"": ""Is Johnson & Johnson (JNJ) Dominating A Billionaire Quant\u2019s Investment Strategy Right Now?"", ""summary"": ""We recently compiled a list of the 10 Stocks Dominating a Billionaire Quant\u2019s Investment Strategy. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other stocks that are dominating a billionaire quant\u2019s investment strategy. AQR Capital Management is a global investment management firm, founded by Cliff [\u2026]""}, {""date"": ""20241208081209"", ""headline"": ""Genmab Is Too Attractive To Ignore"", ""summary"": ""Learn why Genmab's shares are down but poised for growth in the long-term with strong revenue projections and pipeline expansion.""}, {""date"": ""20241208162100"", ""headline"": ""DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) today announced data from the Phase 3 AQUILA study showing that DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) significantly delayed progression from high-risk smoldering multiple myeloma (SMM) to active multiple myeloma (MM) and extended overall survival compared to the current standard of care of active monitoring.1 The data were presented for the first time as an oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting (Abstract #7""}, {""date"": ""20241208162700"", ""headline"": ""Advertising Firms Omnicom and Interpublic Nearing Merger That Would Reshape Industry"", ""summary"": ""A deal would create the world\u2019s largest advertising company, with net revenue of more than $20 billion, topping WPP\u2019s $15.1 billion.""}, {""date"": ""20241208173300"", ""headline"": ""TECVAYLI\u00ae (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma"", ""summary"": ""Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI\u00ae (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. The MajesTEC-5 (Abstract #493) and MajesTEC-4 (Abstract #494) studies establish the potential of TECVAYLI\u00ae for use in newly diagnosed patients, with promising efficacy and a tolerable safety profile. These data were highlighted as oral presentations at the 2024 Americ""}, {""date"": ""20241208193000"", ""headline"": ""Johnson & Johnson Announces Data Highlighting That DARZALEX FASPRO (Daratumumab and Hyaluronidase-fihj) Based Regimens Improve Overall and Sidual Disease"", ""summary"": ""Johnson & Johnson announced data highlighting that DARZALEX FASPRO\u00ae -based regimens improve overall and sustained minimal residual disease negativity rates and progression-free survival in patients...""}, {""date"": ""20241208193000"", ""headline"": ""Johnson & Johnson Announces Data from the Phase 3 Acquisitions"", ""summary"": ""Johnson & Johnson announced data highlighting that DARZALEX FASPRO -based regimens improve overall and sustained minimal residual disease negativity rates and progression-free survival in patients...""}, {""date"": ""20241208211400"", ""headline"": ""Apple Tops the List of Best-Managed Companies of 2024"", ""summary"": ""Apple Tops the List of Best-Managed Companies of 2024""}]",{}
5,2024-12-08,148.1243133544922,2024-12-15,145.45567321777344,-0.018016219459746186,D2,"[{""date"": ""20241208081209"", ""headline"": ""Genmab Is Too Attractive To Ignore"", ""summary"": ""Learn why Genmab's shares are down but poised for growth in the long-term with strong revenue projections and pipeline expansion.""}, {""date"": ""20241208162100"", ""headline"": ""DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) today announced data from the Phase 3 AQUILA study showing that DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) significantly delayed progression from high-risk smoldering multiple myeloma (SMM) to active multiple myeloma (MM) and extended overall survival compared to the current standard of care of active monitoring.1 The data were presented for the first time as an oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting (Abstract #7""}, {""date"": ""20241208162700"", ""headline"": ""Advertising Firms Omnicom and Interpublic Nearing Merger That Would Reshape Industry"", ""summary"": ""A deal would create the world\u2019s largest advertising company, with net revenue of more than $20 billion, topping WPP\u2019s $15.1 billion.""}, {""date"": ""20241208173300"", ""headline"": ""TECVAYLI\u00ae (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma"", ""summary"": ""Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI\u00ae (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. The MajesTEC-5 (Abstract #493) and MajesTEC-4 (Abstract #494) studies establish the potential of TECVAYLI\u00ae for use in newly diagnosed patients, with promising efficacy and a tolerable safety profile. These data were highlighted as oral presentations at the 2024 Americ""}, {""date"": ""20241208193000"", ""headline"": ""Johnson & Johnson Announces Data Highlighting That DARZALEX FASPRO (Daratumumab and Hyaluronidase-fihj) Based Regimens Improve Overall and Sidual Disease"", ""summary"": ""Johnson & Johnson announced data highlighting that DARZALEX FASPRO\u00ae -based regimens improve overall and sustained minimal residual disease negativity rates and progression-free survival in patients...""}, {""date"": ""20241208193000"", ""headline"": ""Johnson & Johnson Announces Data from the Phase 3 Acquisitions"", ""summary"": ""Johnson & Johnson announced data highlighting that DARZALEX FASPRO -based regimens improve overall and sustained minimal residual disease negativity rates and progression-free survival in patients...""}, {""date"": ""20241209003000"", ""headline"": ""DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) today announced data highlighting that DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) negativity rates and progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.1,2 These findings were demonstrated in an expanded MRD analysis of the Phase 3 CEPHEUS study (Abstract #362) and a post hoc analysis of clinically relevant s""}, {""date"": ""20241209021400"", ""headline"": ""Apple Tops the List of Best-Managed Companies of 2024"", ""summary"": ""Tech companies hold six of the top 10 spots, while Mastercard jumped to fifth place from 24th last year.""}, {""date"": ""20241209064408"", ""headline"": ""J&J: positive data in multiple myeloma"", ""summary"": ""Johnson & Johnson announces that a Phase 3 study demonstrated that Darzalex Faspro significantly delayed the progression of high-risk indolent multiple myeloma to active multiple myeloma , while...""}, {""date"": ""20241209065618"", ""headline"": ""J&J: promising data for Tecvayli in myeloma"", ""summary"": ""Johnson & Johnson announces promising data on Tecvayli from two studies , presented at ASH 2024. These trials explore the use of Tecvayli in patients with newly diagnosed multiple myeloma , and...""}, {""date"": ""20241209092617"", ""headline"": ""Johnson & Johnson - DARZALEX FASPRO -based regimens demonstrate improved rates of minimal residual disease negativity and progression-free survival in patients with newly diagnosed multiple myeloma"", ""summary"": ""SAN DIEGO - Johnson & Johnson today announced data highlighting that DARZALEX FASPRO -based regimens improve overall and sustained minimal residual disease negativity rates and progression-free...""}, {""date"": ""20241209092824"", ""headline"": ""Johnson & Johnson - TECVAYLI demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma"", ""summary"": ""SAN DIEGO - Johnson & Johnson today announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed multiple myeloma in induction and maintenance...""}, {""date"": ""20241209094415"", ""headline"": ""J&J: studies the potential of nipocalamib in anemia"", ""summary"": ""Johnson & Johnson presented the results of several studies on warm autoimmune hemolytic anemia at the 2024 annual meeting of the American Society of Hematology.Affecting around one in 8,000 people,...""}, {""date"": ""20241209113056"", ""headline"": ""Johnson & Johnson Says 2 Studies of Potential Early Multiple Myeloma Drug Showed 'Promising' Efficacy"", ""summary"": ""Johnson & Johnson (JNJ) said Sunday that data from two investigational studies of its drug Tecvayli""}, {""date"": ""20241209130000"", ""headline"": ""Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) announced today findings from several online abstracts and posters on patients living with warm autoimmune hemolytic anemia (wAIHA), a rare, life-threatening condition where autoantibodies lead to the premature destruction of red blood cells, at the 2024 American Society of Hematology (ASH) Annual Meeting. These findings underscore the significant disease burden for the estimated one in 8,000 people living with wAIHA, including the high unmet need for targeted thera""}, {""date"": ""20241209130013"", ""headline"": ""Institutional investors may adopt severe steps after Johnson & Johnson's (NYSE:JNJ) latest 3.5% drop adds to a year losses"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Johnson & Johnson's stock price might be vulnerable to...""}, {""date"": ""20241209134500"", ""headline"": ""GSK Gets Positive Results in Blood-Cancer Drug Trial"", ""summary"": ""GSK Gets Positive Results in Blood-Cancer Drug Trial""}, {""date"": ""20241209155035"", ""headline"": ""Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead."", ""summary"": ""Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.""}, {""date"": ""20241210003000"", ""headline"": ""CARVYKTI\u00ae (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study"", ""summary"": ""Johnson & Johnson (NYSE:JNJ) announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI\u00ae (ciltacabtagene autoleucel; cilta-cel) significantly increased minimal residual disease (MRD) negativity rates (10-5) in patients with relapsed or refractory multiple myeloma (RRMM) who were lenalidomide-refractory and had received one to three prior lines of therapy, including a proteasome inhibitor (PI), compared to standard therapies of pomalidomide, bortezomib""}, {""date"": ""20241210024000"", ""headline"": ""Market Leadership Is Narrow. Your Portfolio Shouldn't Be"", ""summary"": ""2024 S&P 500 Index performance has been among some of the strongest in history, adding to similarly strong performance in recent years.""}, {""date"": ""20241210045701"", ""headline"": ""IGD Continues To Show Improvements, Now Covering Distribution"", ""summary"": ""Voya Global Equity Dividend and Premium Opportunity Fund offers a high 10.70% yield, higher than most of its peers. Find out my recommendation for IGD.""}, {""date"": ""20241210121654"", ""headline"": ""Johnson & Johnson : 2024 Fourth-Quarter Press Release & Supplemental Schedules"", ""summary"": ""Media contact: Investor contact: ...""}, {""date"": ""20241210130000"", ""headline"": ""Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results"", ""summary"": ""NEW BRUNSWICK, N.J., December 10, 2024--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson\u2019s""}, {""date"": ""20241210154255"", ""headline"": ""Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends"", ""summary"": ""67 Aristocrats span all sectors, with BEN topping yields. Read why its strong dividend history and low price make it a December buy, despite analyst concerns.""}, {""date"": ""20241210162743"", ""headline"": ""Retired Investor Living Off $160,000 In Dividends Shares Stock Portfolio \u2013 'We Live Quite Comfortably On Dividends'"", ""summary"": ""Investing in dividend stocks is an effective strategy for securing a reliable income stream during retirement. A study from Ned Davis Research showed that dividend stocks returned about 8.8% annually in aggregate between 1972 and 2012, compared with ...""}, {""date"": ""20241210163100"", ""headline"": ""Johnson & Johnson stock underperforms Tuesday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Tuesday when compared to competitors""}, {""date"": ""20241210224510"", ""headline"": ""Johnson & Johnson (JNJ) Stock Moves -0.25%: What You Should Know"", ""summary"": ""In the latest trading session, Johnson & Johnson (JNJ) closed at $149.23, marking a -0.25% move from the previous day.""}, {""date"": ""20241211042042"", ""headline"": ""Why Is Johnson & Johnson (JNJ) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?"", ""summary"": ""We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other cosmetic surgery and aesthetics stocks. In the face of economic uncertainty, consumer preferences in the beauty industry are [\u2026]""}, {""date"": ""20241211104138"", ""headline"": ""ASH 2024: J&J\u2019s Tecvayli shows promise in transplant-eligible NDMM patient"", ""summary"": ""GlobalData\u2019s patient-based forecast predicts Tecvayli will reach a peak of $2.1bn in sales globally by 2030 in MM.""}, {""date"": ""20241211121545"", ""headline"": ""Johnson & Johnson reinstated with a Neutral at BofA"", ""summary"": ""BofA reinstated coverage of Johnson & Johnson with a Neutral rating and $166 price target The current valuation at a premium to other drug names \u201cseems likely to cap upside,\u201d the analyst tells investors while reinstating coverage of 11 large-cap U.S. pharma and biotech stocks. J&J has a \u201cfairly interesting pipeline\u201d and talc litigation resolution in 2025 \u201cwould help,\u201d the analyst added. Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>""}, {""date"": ""20241211124000"", ""headline"": ""Pioneer Disciplined Value Fund Q3 2024 Performance And Market Commentary"", ""summary"": ""Pioneer Disciplined Value focuses on mispriced quality, sustainable US large-cap companies trading at attractive valuations with the goal of maximizing risk-adjusted returns.""}, {""date"": ""20241211163100"", ""headline"": ""Johnson & Johnson stock underperforms Wednesday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Wednesday when compared to competitors""}, {""date"": ""20241212052100"", ""headline"": ""Pioneer Equity Income Fund Q3 2024 Performance And Market Commentary"", ""summary"": ""For the third quarter of 2024, Pioneer Equity Income Fund\u00e2\u0080\u0099s Class Y shares underperformed the Fund\u00e2\u0080\u0099s benchmark, the RLV, returning 7.77% vs 9.43% respectively.""}, {""date"": ""20241212085011"", ""headline"": ""Johnson & Johnson : U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients"", ""summary"": ""Impella 5.5 and Impella CP are the first left-sided, minimally invasive temporary mechanical circulatory support options for pediatric patients with symptomatic ADHF and cardiogenic shock ...""}, {""date"": ""20241212104709"", ""headline"": ""J&J: FDA extends indication for Impella heart pumps"", ""summary"": ""Johnson & Johnson MedTech announces that the FDA has extended the indications for the Impella 5.5 and Impella CP heart pumps with SmartAssist to include certain pediatric patients with acute...""}, {""date"": ""20241212163104"", ""headline"": ""Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference"", ""summary"": ""Johnson & Johnson will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief...""}, {""date"": ""20241212192318"", ""headline"": ""These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over"", ""summary"": ""It's been a banner year for the stock market.  Boeing (NYSE: BA) has had a rough year.  It started early as the stock price fell after the door panel on a Boeing jet flown by Alaska Airlines popped off mid-flight.""}, {""date"": ""20241213113427"", ""headline"": ""FDA grants PMA approval to J&J MedTech\u2019s heart pumps for paediatric use"", ""summary"": ""The company has collaborated with ACTION to gather real-world data supporting the on-label use of heart pumps.""}, {""date"": ""20241213130034"", ""headline"": ""Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?"", ""summary"": ""With its stock down 12% over the past three months, it is easy to disregard Johnson & Johnson (NYSE:JNJ). However...""}, {""date"": ""20241213140017"", ""headline"": ""Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""20241213163100"", ""headline"": ""Johnson & Johnson stock outperforms competitors on strong trading day"", ""summary"": ""Johnson & Johnson stock outperforms competitors on strong trading day""}, {""date"": ""20241213171507"", ""headline"": ""Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report"", ""summary"": ""The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes. Gilead Sciences Inc's (NASDAQ:GILD) Biktarvy, Johnson & Johnson's (NYSE:JNJ) Darzalex, Novartis AG's (NYSE:NVS) Entresto, Exelixis Inc (NASDAQ:EXEL) Cabometyx, and Pfizer Inc's (NYSE:PFE) Xeljanz are among the five drugs flagged for unsupported price increases. These five drugs' unsupported net price increases produce""}, {""date"": ""20241213172227"", ""headline"": ""Imerys - Mining Value"", ""summary"": ""Imerys S.A. has struggled with subdued industrial demand but shows signs of recovery with an 11% one-year return. Learn more about IMYSF stock here.""}, {""date"": ""20241213205500"", ""headline"": ""J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds"", ""summary"": ""Pharmaceutical company claims Cigna units worked with SaveOn and caused J&J to pay more than $100 million in copay assistance than it would have otherwise.""}, {""date"": ""20241213235416"", ""headline"": ""Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value"", ""summary"": ""Learn how to maximize returns by focusing on high-conviction stocks across diverse sectors and using proven investment strategies.""}]",{}
6,2024-12-15,145.45567321777344,2024-12-22,143.32275390625,-0.014663706573548874,D2,"[{""date"": ""20241216090417"", ""headline"": ""J&J: applies to the FDA for an expanded indication for Simponi"", ""summary"": ""Johnson & Johnson announced today that it has applied to the U.S. Food & Drug Administration for expanded approval of Simponi for the treatment of children aged 2 and over with moderately to severely...""}, {""date"": ""20241216121251"", ""headline"": ""PFA to surpass radiofrequency ablation in 2025: Citi survey"", ""summary"": ""Pulsed field ablation could soon be used in the majority of electrophysiology procedures to treat atrial fibrillation as Medtronic, Boston Scientific and Johnson & Johnson battle for market share.""}, {""date"": ""20241216122300"", ""headline"": ""EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease"", ""summary"": ""The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.""}, {""date"": ""20241216155200"", ""headline"": ""Dow's 111-point drop led by losses for UnitedHealth, Verizon shares"", ""summary"": ""Dow's 111-point drop led by losses for UnitedHealth, Verizon shares""}, {""date"": ""20241216163100"", ""headline"": ""Johnson & Johnson stock underperforms Monday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Monday when compared to competitors""}, {""date"": ""20241216190530"", ""headline"": ""Market Chatter: Johnson & Johnson Sues Cigna Units Over Alleged Drug Fund Misuse"", ""summary"": ""Johnson & Johnson (JNJ) is suing Cigna's divisions, Express Scripts and Accredo, claiming they worke""}, {""date"": ""20241216224517"", ""headline"": ""Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors"", ""summary"": ""In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous trading day.""}, {""date"": ""20241217042318"", ""headline"": ""J&J: FDA delays approval of Rybrevant in NSCLC"", ""summary"": ""Johnson & Johnson announces that it has received a Complete Response Letter from the U.S. Food and Drug Administration following its Biologics License Application for the subcutaneous fixed...""}, {""date"": ""20241217100048"", ""headline"": ""Johnson & Johnson - Update on U.S. regulatory review of subcutaneous amivantamab"", ""summary"": ""RARITAN - Johnson & Johnson today announced the U.S. Food and Drug Administration has issued a Complete Response Letter for the Biologics License Application for a fixed combination of amivantamab...""}, {""date"": ""20241217100048"", ""headline"": ""Johnson & Johnson submits application seeking U.S. FDA approval of SIMPONI for the treatment of pediatric ulcerative colitis"", ""summary"": ""HORHSAM - Johnson & Johnson today announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking expanded approval of SIMPONI for the...""}, {""date"": ""20241217120027"", ""headline"": ""Johnson & Johnson (NYSE:JNJ) Has A Pretty Healthy Balance Sheet"", ""summary"": ""David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...""}, {""date"": ""20241217132100"", ""headline"": ""FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC"", ""summary"": ""The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.""}, {""date"": ""20241217163100"", ""headline"": ""Johnson & Johnson stock outperforms competitors on strong trading day"", ""summary"": ""Johnson & Johnson stock outperforms competitors on strong trading day""}, {""date"": ""20241217171335"", ""headline"": ""The Take On Tyra Biosciences"", ""summary"": ""Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg.""}, {""date"": ""20241218081000"", ""headline"": ""My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys"", ""summary"": ""Financial writer achieves record dividend income in November through investments in BDCs, inching closer to $10,000 annual goal.""}, {""date"": ""20241218082942"", ""headline"": ""Johnson & Johnson : submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA\u00ae (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant"", ""summary"": ""Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA \u00ae in adult patients with...""}, {""date"": ""20241218100416"", ""headline"": ""J&J: applies to the EMA for an expanded indication for Imbruvica"", ""summary"": ""J&J announces that its subsidiary Janssen-Cilag International has applied to the European Medicines Agency to extend the indication of Imbruvica in combination with the R-CHOP protocol in the...""}, {""date"": ""20241218101500"", ""headline"": ""The Smartest Dividend Stocks to Buy With $500 Right Now"", ""summary"": ""If you add a few dividend stocks to your portfolio, you'll start collecting returns on a regular basis -- without lifting a finger.  Loads of companies pay dividends, so it might seem difficult make a selection.  A great way to start is to consider the list of Dividend Kings, companies that have increased their dividend payments for at least 50 consecutive years.""}, {""date"": ""20241218103350"", ""headline"": ""Johnson & Johnson Participates in the Inauguration of World Health Organization Academy to Improve Training and Education of Health Workers Globally"", ""summary"": ""Lyon, France - Johnson & Johnson participated today along with the Government of France and health care leaders from around the world in the inauguration of the WHO Academy campus in Lyon, France.The...""}, {""date"": ""20241218103815"", ""headline"": ""Johnson & Johnson Participates in the Inauguration of World Health Organization (WHO) Academy to Improve Training and Education of Health Workers Globally"", ""summary"": ""Lyon, France - Johnson & Johnson participated today along with the Government of France and health care leaders from around the world in the inauguration of the WHO Academy campus in Lyon, France.The...""}, {""date"": ""20241218114500"", ""headline"": ""Tessera gets sickle cell funding; Corvus shares slide on eczema data"", ""summary"": ""The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera\u2019s in vivo sickle cell therapy. Elsewhere, Cara agreed to a reverse merger and J&J had a drug application rejected.""}, {""date"": ""20241218132100"", ""headline"": ""SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study"", ""summary"": ""Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.""}, {""date"": ""20241218141509"", ""headline"": ""Of 63 Fortune500 Industry Leaders, 57 Pay Dividends, 38 Test 'Safer' & 1 Is Ideal To Buy"", ""summary"": ""Top 10 Fortune 500 industry leaders show strong yields. See why Energy Transfer\u00e2\u0080\u0099s high-dividend, low-price stock stands out as a safer buy in December.""}, {""date"": ""20241218163100"", ""headline"": ""Johnson & Johnson stock underperforms Wednesday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Wednesday when compared to competitors""}, {""date"": ""20241218195620"", ""headline"": ""Jim Cramer on Johnson & Johnson (JNJ): How the Pharma Giant is Handling Billion-Dollar Lawsuits and Legal Battles"", ""summary"": ""We recently published a list of the Jim Cramer Just Discussed These 13 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed recently. As the Federal Reserve exits the year by having continued its interest rate cuts, Wall Street [\u2026]""}, {""date"": ""20241219110000"", ""headline"": ""Johnson & Johnson: Dividend Legend At A Discount"", ""summary"": ""JNJ is a strong defensive play with diversified revenue streams, impressive growth investments, and attractive stock valuation. Read why JNJ is a Strong Buy.""}, {""date"": ""20241219111654"", ""headline"": ""Why Is Johnson & Johnson (JNJ) Among the Best Dividend Stocks to Invest In?"", ""summary"": ""We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other dividend stocks. Dividend-focused investors are often drawn to stocks with high yields, shaping their strategies around acquiring such investments. [\u2026]""}, {""date"": ""20241219163100"", ""headline"": ""Johnson & Johnson stock underperforms Thursday when compared to competitors"", ""summary"": ""Johnson & Johnson stock underperforms Thursday when compared to competitors""}, {""date"": ""20241220163100"", ""headline"": ""Johnson & Johnson stock rises Friday, still underperforms market"", ""summary"": ""Johnson & Johnson stock rises Friday, still underperforms market""}, {""date"": ""20241220183005"", ""headline"": ""The 10 biggest medtech stories of 2024"", ""summary"": ""The medtech space in 2024 has been marked by regulatory rulings, blockbuster acquisitions and cybersecurity challenges.""}, {""date"": ""20241220191351"", ""headline"": ""Is Johnson & Johnson (JNJ) a Cheap NYSE Stock to Invest in Now?"", ""summary"": ""We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other cheap NYSE stocks to invest in now. The stock market appears poised for another year of impressive returns, likely extending into 2025. [\u2026]""}, {""date"": ""20241221093000"", ""headline"": ""If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy"", ""summary"": ""The methodology uses earnings yield, dividend yield, and 5-year dividend CAGR to score and rank 55 stocks across all 11 sectors.""}, {""date"": ""20241222105900"", ""headline"": ""Hartford Balanced Income Fund Q3 2024 Commentary"", ""summary"": ""Hartford Balanced Income Fund (I-share) underperformed its benchmark. US equities rose for the fourth consecutive quarter to register a robust year-to-date gain.""}]",{}
7,2024-12-22,143.32275390625,2024-12-29,143.8981475830078,0.0040146708116854946,U1,"[{""date"": ""20241222105900"", ""headline"": ""Hartford Balanced Income Fund Q3 2024 Commentary"", ""summary"": ""Hartford Balanced Income Fund (I-share) underperformed its benchmark. US equities rose for the fourth consecutive quarter to register a robust year-to-date gain.""}, {""date"": ""20241223051500"", ""headline"": ""Hartford Healthcare Fund Q3 2024 Commentary"", ""summary"": ""The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.""}, {""date"": ""20241223094600"", ""headline"": ""Hartford Equity Income Fund Q3 2024 Commentary"", ""summary"": ""Hartford Equity Income Fund (I Share) underperformed the Russell 1000 Value Index during the quarter. Read more here.""}, {""date"": ""20241223102500"", ""headline"": ""A Bull Market Is Here: 2 Super Stocks Down 21% and 30% to Buy Right Now"", ""summary"": ""Meanwhile, the more growth-heavy Nasdaq Composite index has delivered a total return of 30%.  This year's performance has marked one of the most impressive annual bull runs in stock market history, and major indexes have managed to notch new highs at multiple points across the stretch.  Keith Noonan: Uber Technologies (NYSE: UBER) is the leader in the ride-hailing market, and it's been serving up some pretty impressive sales and margin growth.""}, {""date"": ""20241223112006"", ""headline"": ""Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?"", ""summary"": ""Sector ETF report for IHE""}, {""date"": ""20241223140005"", ""headline"": ""These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar"", ""summary"": ""Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.""}, {""date"": ""20241223163100"", ""headline"": ""Johnson & Johnson stock rises Monday, still underperforms market"", ""summary"": ""Johnson & Johnson stock rises Monday, still underperforms market""}, {""date"": ""20241223224518"", ""headline"": ""Johnson & Johnson (JNJ) Ascends But Remains Behind Market: Some Facts to Note"", ""summary"": ""In the most recent trading session, Johnson & Johnson (JNJ) closed at $145.27, indicating a +0.55% shift from the previous trading day.""}, {""date"": ""20241224103400"", ""headline"": ""Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend Stocks"", ""summary"": ""The best dividend stocks will send you more money each year by increasing their payments.  Anybody can gift oneself with a multiyear supply of passive income by purchasing shares of a high-quality dividend-paying company.  Three great ones to consider buying are Coca-Cola (NYSE: KO), Johnson & Johnson (NYSE: JNJ), and NextEra Energy (NYSE: NEE).""}, {""date"": ""20241224163100"", ""headline"": ""Johnson & Johnson stock rises Tuesday, still underperforms market"", ""summary"": ""Johnson & Johnson stock rises Tuesday, still underperforms market""}, {""date"": ""20241226075149"", ""headline"": ""Kairos Pharma: Potential To Remove Resistance With Established Drugs"", ""summary"": ""Kairos Pharma's ENV-105 aims to overcome resistance in CRPC and EGFR-mutant NSCLC, with key data releases expected in 2025. Explore more details here.""}, {""date"": ""20241226103500"", ""headline"": ""The Smartest Dividend Stocks to Buy With $1,000 Right Now"", ""summary"": ""Here are three dividend stocks to consider for your long-term portfolio.  If you're about to yawn at the thought of a huge telecommunications company, stop -- and check out AT&T's (NYSE: T) recent dividend yield: 4.9%.  AT&T has recently sold off its 70% stake in DirecTV, generating a lot of cash that can be used to pay down debt and to reward shareholders.""}, {""date"": ""20241226140000"", ""headline"": ""How To Build A Strategically Balanced $50,000 Dividend Portfolio To Be Well-Positioned For 2025"", ""summary"": ""Learn how to build a $50,000 dividend portfolio to position yourself well for 2025 with a focus on dividend income, growth, and diversification.""}, {""date"": ""20241226140019"", ""headline"": ""Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""20241226154208"", ""headline"": ""US FDA proposes standardized testing to detect asbestos in talc products"", ""summary"": ""Asbestos, a known human carcinogen, can be injurious to consumers if found in talc-containing cosmetic products as there is no established \""safe level\"" threshold for exposure to the substance.  If finalized, the rule can help protect consumers from harmful exposure to asbestos, leading to fewer illnesses such as lung and ovarian cancers, the health regulator said.  Johnson & Johnson is facing lawsuits from more than 62,000 claimants, who have alleged that the company's baby powder and other talc products were contaminated with asbestos and caused ovarian and other cancers.""}, {""date"": ""20241226205327"", ""headline"": ""Sector Update: Health Care Stocks Edge Higher Late Afternoon"", ""summary"": ""Health care stocks edged up late Thursday afternoon, with the NYSE Health Care Index up 0.1% and the""}, {""date"": ""20241227062311"", ""headline"": ""J&J: exclusive agreement with Karen Pharmaceutical"", ""summary"": ""Johnson & Johnson announces that it has entered into an exclusive agreement with Kaken Pharmaceutical for the worldwide development, manufacture and commercialization of the STAT6 program for...""}, {""date"": ""20241227101215"", ""headline"": ""Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis"", ""summary"": ""NEW BRUNSWICK - Johnson & Johnson1 announced today that it has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for...""}, {""date"": ""20241227121700"", ""headline"": ""JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723"", ""summary"": ""Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.""}, {""date"": ""20241227152129"", ""headline"": ""Duvakitug And Teva's Growth: A Game Changer In Pharma"", ""summary"": ""Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here to find out why TEVA is a Buy.""}, {""date"": ""20241227212506"", ""headline"": ""Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal"", ""summary"": ""Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a \u201cpositive readthrough\u201d from the J&J\u2019s (JNJ) in-licensing of an oral STAT6 program from Kaken Pharmaceutical. Kymera has recently started a Phase 1 for STAT6 degrader KT-621, while JNJ announced an in-licensing deal with Japan-based Kaken Pharmaceutical for small molecule STAT6 program KP-723, and while there are limited data publicly available about KP-723, the deal serves as""}]",{}
8,2024-12-29,143.8981475830078,2025-01-05,143.04498291015625,-0.005928948267797662,D1,"[{""date"": ""20241230100600"", ""headline"": ""5 Unbeatable Stocks I'm Eager to Buy in 2025"", ""summary"": ""These value, growth, and income stocks are incredibly cheap in a historically pricey stock market.""}, {""date"": ""20241230222851"", ""headline"": ""Is Johnson & Johnson (JNJ) the Best Pharma Dividend Stock to Buy In 2024?"", ""summary"": ""We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but [\u2026]""}, {""date"": ""20241231024119"", ""headline"": ""Halozyme: Recent Approvals Alter My Appetite"", ""summary"": ""Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's stock price. Read more here.""}, {""date"": ""20241231063912"", ""headline"": ""Johnson & Johnson - European Commission approves RYBREVANT in combination with LAZCLUZE for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer"", ""summary"": ""BEERSE, BELGIUM - Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission has approved a Type II variation extension of indication for RYBREVANT , in...""}, {""date"": ""20241231093039"", ""headline"": ""Here\u2019s Why WisdomTree U.S. LargeCap Dividend Fund (DLN) Is One of the Best Performing Dividend ETFs in 2024"", ""summary"": ""We recently compiled a list of the 10 Best Performing Dividend ETFs In 2024. In this article, we are going to take a look at where WisdomTree U.S. LargeCap Dividend Fund (NYSE:DLN) stands against the other dividend ETFs. By the end of 2023, the global ETF market had reached $11.1 trillion in assets under management (AUM) [\u2026]""}, {""date"": ""20241231130013"", ""headline"": ""Investors in Johnson & Johnson (NYSE:JNJ) have unfortunately lost 8.8% over the last three years"", ""summary"": ""For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you...""}, {""date"": ""20241231185759"", ""headline"": ""Is Johnson & Johnson (JNJ) Among the Best Low Volatility Stocks to Buy Right Now?"", ""summary"": ""We recently published a list of 8 Best Low Volatility Stocks To Buy Right Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best low volatility stocks to buy right now. The market has shown strong performance overall, with the S&P 500 up nearly [\u2026]""}, {""date"": ""20241231224519"", ""headline"": ""Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note"", ""summary"": ""The latest trading day saw Johnson & Johnson (JNJ) settling at $144.62, representing a +0.89% change from its previous close.""}, {""date"": ""20250101120300"", ""headline"": ""The 5 worst-performing stocks on the Dow Jones Industrial Average in 2024"", ""summary"": ""The Dow's biggest losers include companies in the aerospace, biopharma, and sports apparel sectors.""}, {""date"": ""20250101171014"", ""headline"": ""Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?"", ""summary"": ""Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.""}, {""date"": ""20250102042700"", ""headline"": ""The Descent of an Army Vet Turned Corporate Consultant Named in the New Year\u2019s Attack"", ""summary"": ""Texas born and bred, Shamsud-Din Jabbar worked at Deloitte before plowing a truck with an Islamic State flag into a New Orleans crowd.""}, {""date"": ""20250102052000"", ""headline"": ""Not A Year For The 2024 Dogs Of The Dow"", ""summary"": ""With the close of trading for 2024 occurring on Tuesday, it is time to look at the performance of those Dogs of the Dow. Read more here.""}, {""date"": ""20250102080000"", ""headline"": ""3 Of The Most Consistent Dividend Stocks For Retirees"", ""summary"": ""Discover three super-consistent dividend stocks for retirees, offering steadily rising income, safety, and attractive valuations in a volatile market. Learn more on these 3 stocks here.""}, {""date"": ""20250102101615"", ""headline"": ""J&J: announces 1st quarter 2025 dividend"", ""summary"": ""Johnson & Johnson announced today that its Board of Directors has declared a first-quarter dividend of $1.24 per share on the company's common stock. The dividend is payable on March 4, 2025 to...""}, {""date"": ""20250102122143"", ""headline"": ""January Dow Dogs: 1 'Safer' Buy, And 5 With Promise"", ""summary"": ""Get insights on top Dow Dogs like Verizon and Merck, with potential net gains forecasted by analysts. Click for the January picks.""}, {""date"": ""20250102130000"", ""headline"": ""Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025"", ""summary"": ""NEW BRUNSWICK, N.J., January 02, 2025--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2025 of $1.24 per share on the company\u2019s common stock. The dividend is payable on March 4, 2025 to shareholders of record at the close of business on February 18, 2025. The ex-dividend date is February 18, 2025.""}, {""date"": ""20250102161142"", ""headline"": ""Johnson & Johnson Declares Dividend, Short Interest Declines"", ""summary"": ""Johnson & Johnson Announces Dividend Amid Positive Investor Sentiment and New Drug Approval""}, {""date"": ""20250102162203"", ""headline"": ""Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops"", ""summary"": ""Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops""}, {""date"": ""20250102163100"", ""headline"": ""Johnson & Johnson stock outperforms competitors despite losses on the day"", ""summary"": ""Johnson & Johnson stock outperforms competitors despite losses on the day""}, {""date"": ""20250102200000"", ""headline"": ""5 Low-Leverage Stocks Worth Adding to Your Portfolio in 2025"", ""summary"": ""The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy FOX, NWG, ATR, JNJ and REVG.""}, {""date"": ""20250103163100"", ""headline"": ""Johnson & Johnson stock rises Friday, still underperforms market"", ""summary"": ""Johnson & Johnson stock rises Friday, still underperforms market""}, {""date"": ""20250104080000"", ""headline"": ""5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (January 2025)"", ""summary"": ""Discover top dividend-paying stocks with discounts on historical norms. Filtered from 7,500+ companies.""}, {""date"": ""20250104120028"", ""headline"": ""This Johnson & Johnson Insider Reduced Their Stake By 37%"", ""summary"": ""From what we can see, insiders were net sellers in Johnson & Johnson's ( NYSE:JNJ ) during the past 12 months. That is...""}]","{""assetTurnoverTTM"": 0.4994, ""bookValue"": 71490, ""cashRatio"": 0.17966654080801256, ""currentRatio"": 1.1107, ""ebitPerShare"": 1.6002, ""eps"": 1.4125, ""ev"": 372701.7, ""fcfMargin"": 0.2385, ""fcfPerShareTTM"": 8.2437, ""grossMargin"": 0.6844, ""inventoryTurnoverTTM"": 2.3226, ""longtermDebtTotalAsset"": 0.1702, ""longtermDebtTotalCapital"": 0.2835, ""longtermDebtTotalEquity"": 0.4287, ""netDebtToTotalCapital"": 0.2552, ""netDebtToTotalEquity"": 0.386, ""netMargin"": 0.1524, ""operatingMargin"": 0.1726, ""payoutRatioTTM"": 0.8405, ""pb"": 4.8274, ""peTTM"": 24.535, ""pfcfTTM"": 17.3928, ""pretaxMargin"": 0.1726, ""psTTM"": 3.8854, ""ptbv"": 10.1886, ""quickRatio"": 0.7823, ""receivablesTurnoverTTM"": 5.9782, ""roaTTM"": 0.0791, ""roeTTM"": 0.1987, ""roicTTM"": 0.1306, ""rotcTTM"": 0.155, ""salesPerShare"": 9.2709, ""sgaToSale"": 0.3156, ""tangibleBookValue"": 33872, ""totalDebtToEquity"": 0.5124, ""totalDebtToTotalAsset"": 0.2034, ""totalDebtToTotalCapital"": 0.3388, ""totalRatio"": 1.6582, ""period"": ""2024-12-29""}"
9,2025-01-05,143.04498291015625,2025-01-12,140.931884765625,-0.014772263252731066,D2,"[{""date"": ""20250106080000"", ""headline"": ""4 closely watched FDA approval dates in 2025 from J&J, Novo and more"", ""summary"": ""A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in the new year.""}, {""date"": ""20250106120000"", ""headline"": ""How Are Companies Using AI Agents? Here\u2019s a Look at Five Early Users of the Bots"", ""summary"": ""Artificial intelligence agents have emerged as one of the most exciting aspects of generative AI for business because they take chatbots to the next level, performing complex tasks without help from humans.""}, {""date"": ""20250106165400"", ""headline"": ""Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?"", ""summary"": ""Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.""}, {""date"": ""20250106180000"", ""headline"": ""My Top 10 Dividend-Paying Buy-And-Hold Stocks For 2025"", ""summary"": ""Top 10 dividend-paying buy-and-hold stocks for your portfolio, offering both stability and growth potential over the next decade. Click here to find out more.""}, {""date"": ""20250107080000"", ""headline"": ""Subcutaneous options offer convenience for patients \u2014 and a valuable window for drugmakers"", ""summary"": ""New formulations for under-the-skin application of drugs give pharmas another opening in a crowded market.""}, {""date"": ""20250107091315"", ""headline"": ""Johnson & Johnson Drug Combination Shows Positive Results in Lung Cancer Study"", ""summary"": ""By Sabela Ojea Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung...""}, {""date"": ""20250107110000"", ""headline"": ""Johnson & Johnson: I'm Saying Yes To This Mess"", ""summary"": ""Discover why JNJ's long-term buy rating is supported by its blue-chip status, profitability, and diverse revenue lines, despite recent challenges.""}, {""date"": ""20250107113119"", ""headline"": ""Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)"", ""summary"": ""Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.""}, {""date"": ""20250107130000"", ""headline"": ""RYBREVANT\u00ae (amivantamab-vmjw) plus LAZCLUZE\u2122 (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib"", ""summary"": ""Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating RYBREVANT\u00ae (amivantamab-vmjw) plus LAZCLUZE\u2122 (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. The chemotherapy-free combination regi""}, {""date"": ""20250107153255"", ""headline"": ""Buy 1 January S&P 500 Dividend Aristocrat Out Of 38 'Safer'"", ""summary"": ""HRL leads top Aristocrats for January with a 59-year dividend streak. Discover why its high yield and low price make it a strong pick for 2025.""}, {""date"": ""20250107154054"", ""headline"": ""Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)"", ""summary"": ""Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. Read more about Legend's plans in 2025.""}, {""date"": ""20250107161434"", ""headline"": ""J&J Says Lung Cancer Combo Improves Survival More Than Standard of Care"", ""summary"": ""(Bloomberg) -- Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc\u2019s blockbuster Tagrisso in a head-to-head study, a finding that could change the standard of care for one of the most deadly tumor types.Most Read from BloombergNYC\u2019s Subway Violence Deters Drive to Bring Workers Back to OfficeCan American Drivers Learn to Love Roundabouts?Dutch Central Bank Restores Amsterdam\u2019s \u2018Ugliest Building\u2019Don\u2019t Shrink the BusCan States Hit the Brakes on Runaway Roadb""}, {""date"": ""20250107163100"", ""headline"": ""Johnson & Johnson stock outperforms competitors on strong trading day"", ""summary"": ""Johnson & Johnson stock outperforms competitors on strong trading day""}, {""date"": ""20250107181600"", ""headline"": ""Top Research Reports for NVIDIA, Meta Platforms & Johnson & Johnson"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Meta Platforms, Inc. (META) and Johnson & Johnson (JNJ), as well as two micro-cap stocks Rave Restaurant Group, Inc. (RAVE) and EVI Industries, Inc. (EVI).""}, {""date"": ""20250107222855"", ""headline"": ""Johnson & Johnson: A Potential Beneficiary Of A Great Rotation"", ""summary"": """"}, {""date"": ""20250107224520"", ""headline"": ""Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors"", ""summary"": ""Johnson & Johnson (JNJ) reachead $146.18 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.""}, {""date"": ""20250108040147"", ""headline"": ""VOOV: S&P 500 Value Over Growth In 2025, Solid Macro Backdrop"", ""summary"": ""The Vanguard S&P 500 Value ETF (VOOV) is a strong choice for long-term investors in 2024, offering solid performance and growth potential. See more here.""}, {""date"": ""20250108065611"", ""headline"": ""J&J: positive ph.III results in lung cancer"", ""summary"": ""Johnson & Johnson announces positive results from a phase 3 study evaluating Rybrevant and Lazcluze as first-line treatment for EGFR-mutated non-small cell lung cancer . The chemotherapy-free regimen...""}, {""date"": ""20250108084209"", ""headline"": ""Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's"", ""summary"": ""By Colin Kellaher Johnson & Johnson on Wednesday said it has won Food and Drug Administration fast-track designation for its proposed posdinemab treatment for Alzheimer's disease. J&J is...""}, {""date"": ""20250108090000"", ""headline"": ""Latest Memo From Howard Marks: On Bubble Watch"", ""summary"": """"}, {""date"": ""20250108091655"", ""headline"": ""CURE: Analyst Estimates Point To Significant Gains In 2025"", ""summary"": ""The Direxion Daily Healthcare Bull 3X Shares ETF seeks to deliver 300% (3x) of the return of an index focused on large-cap US healthcare stocks.""}, {""date"": ""20250108095300"", ""headline"": ""Merck, Johnson & Johnson share losses lead Dow's 180-point fall"", ""summary"": ""Merck, Johnson & Johnson share losses lead Dow's 180-point fall""}, {""date"": ""20250108095547"", ""headline"": ""Johnson & Johnson - RYBREVANT plus LAZCLUZE shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib"", ""summary"": ""RARITAN - Johnson & Johnson today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival from the Phase 3 MARIPOSA study, evaluating RYBREVANT plus...""}, {""date"": ""20250108104448"", ""headline"": ""J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial"", ""summary"": ""The Phase III MARIPOSA trial involved 1,074 subjects.""}, {""date"": ""20250108121305"", ""headline"": ""Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer"", ""summary"": ""Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to PFE's higher yield.""}, {""date"": ""20250108125901"", ""headline"": ""Johnson & Johnson (JNJ): A Bull Case Theory"", ""summary"": ""We came across a bullish thesis on Johnson & Johnson (NYSE:JNJ) on Business Model Mastery Substack by The Antifragile Investor. In this article, we will summarize the bulls\u2019 thesis on JNJ. Johnson & Johnson (NYSE:JNJ)\u2019s share was trading at $146.23 as of Jan 7th. JNJ\u2019s trailing and forward P/E were 24.17 and 13.76 respectively according to Yahoo [\u2026]""}, {""date"": ""20250108130000"", ""headline"": ""Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease (AD) in the Phase 2b \""AuTonomy\"" study. The internally discovered mAb has shown the potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid (CSF) from treated AD patients, and in blocking the development""}, {""date"": ""20250108134200"", ""headline"": ""The Zacks Analyst Blog Highlights NVIDIA, Meta Platforms, Johnson & Johnson, Rave Restaurant and EVI Industries"", ""summary"": ""NVIDIA, Meta Platforms, Johnson & Johnson, Rave Restaurant and EVI Industries are part of the Zacks top Analyst Blog.""}, {""date"": ""20250108135931"", ""headline"": ""Inari Gets A Fair Bid As Stryker Buys Yet Another High-Growth Asset"", ""summary"": ""Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal dilution. Learn more on SYK stock here.""}, {""date"": ""20250108153413"", ""headline"": ""J&J pauses Varipulse PFA cases in US"", ""summary"": ""The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for the pulsed field ablation system.""}, {""date"": ""20250108172900"", ""headline"": ""San Francisco Police Cancel Time Off as Healthcare Execs Descend"", ""summary"": ""San Francisco Police Cancel Time Off as Healthcare Execs Descend""}, {""date"": ""20250108184447"", ""headline"": ""J&J Falls \u2014 While Boston Scientific, Medtronic Pop \u2014 After Strokes Sideline A Key Product"", ""summary"": ""Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system.""}, {""date"": ""20250108205759"", ""headline"": ""Johnson & Johnson Temporarily Pulls New Treatment for Atrial Fibrillation to Probe Adverse Events"", ""summary"": ""Johnson & Johnson (JNJ) Wednesday said it paused the rollout of Varipulse cardiac device in the US e""}, {""date"": ""20250109070013"", ""headline"": ""J&J: Fast Track status in early-onset Alzheimer's disease"", ""summary"": ""Johnson & Johnson announces that the FDA has granted 'Fast Track' designation to posdinemab , currently in phase 2b for the treatment of early-onset Alzheimer's disease. Posdinemab has demonstrated...""}, {""date"": ""20250109082812"", ""headline"": ""J&J: FDA priority review for MGg"", ""summary"": ""Johnson & Johnson announced that the Biologics License Application for nipocalimab has received Priority Review designation from the U.S. Food and Drug Administration .This product is used for the...""}, {""date"": ""20250109084312"", ""headline"": ""Johnson & Johnson Gets FDA Priority Review of Nipocalimab in Generalized Myasthenia Gravis"", ""summary"": ""By Colin Kellaher Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia...""}, {""date"": ""20250109114820"", ""headline"": ""Johnson & Johnson MedTech pauses Varipulse rollout in US"", ""summary"": ""Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.""}, {""date"": ""20250109130400"", ""headline"": ""Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) patients with generalized myasthenia gravis (gMG), as supported by findings from the Phase 3 Vivacity-MG3 study. The FDA grants Priority Review to applications for medicines that, if approved, would offer significant improvements in the safety""}, {""date"": ""20250109133100"", ""headline"": ""J&J Pauses Sales of Atrial Fibrillation Device, Stock Down"", ""summary"": ""J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.""}, {""date"": ""20250109140013"", ""headline"": ""How to Find Strong Medical Stocks Slated for Positive Earnings Surprises"", ""summary"": ""Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.""}, {""date"": ""20250109170003"", ""headline"": ""Contineum concludes enrolment in Phase II multiple sclerosis therapy trial"", ""summary"": ""The trial is evaluating the efficacy and safety of PIPE-307 in RRMS patients.""}, {""date"": ""20250109180000"", ""headline"": ""Strategically Building A $10,000 Dividend Portfolio: Realty Income As Its Core Position"", ""summary"": ""Learn how holding Realty Income as the largest position in your $10,000 dividend portfolio can reduce risk and maximize income and growth. Read more here.""}, {""date"": ""20250110080000"", ""headline"": ""DLN: Dividend ETF Leading Its Competitors"", ""summary"": ""WisdomTree U.S. LargeCap Dividend Fund ETF provides value with 300 dividend stocks. Read why DLN is better for total return, despite lower yields and growth.""}, {""date"": ""20250110084212"", ""headline"": ""Johnson & Johnson - Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis"", ""summary"": ""SPRING HOUSE - Johnson & Johnson today announced the nipocalimab Biologics License Application received Priority Review designation from the U.S. Food and Drug Administration for the treatment of...""}, {""date"": ""20250110095100"", ""headline"": ""2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid"", ""summary"": ""Among the Dow Jones Industrial Average's 30 components, there are two historically cheap brand-name companies, as well as a new member that's priced for perfection in an imperfect industry.""}, {""date"": ""20250110104308"", ""headline"": ""J&J: obtains CE certification for a catheter"", ""summary"": ""Johnson & Johnson MedTech announces that it has obtained European CE certification for its Dual Energy Thermocool Hermocool Smarttouch SF catheter, designed for the treatment of cardiac arrhythmias....""}, {""date"": ""20250110110209"", ""headline"": ""Johnson & Johnson : MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH\u2122 SF Catheter"", ""summary"": ""Media contact: Diane Pressman Dpressm1@its.jnj.com Anna Loring Aloring1@its.jnj.com ...""}, {""date"": ""20250110132400"", ""headline"": ""FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab"", ""summary"": ""JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.""}, {""date"": ""20250110140000"", ""headline"": ""4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025"", ""summary"": ""These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor.""}, {""date"": ""20250110163200"", ""headline"": ""Johnson & Johnson stock outperforms competitors despite losses on the day"", ""summary"": ""Johnson & Johnson stock outperforms competitors despite losses on the day""}, {""date"": ""20250110165614"", ""headline"": ""A First Take On CG Oncology"", ""summary"": ""CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising Phase 3 data for Cretostimogene. Learn more on CGON stock here.""}, {""date"": ""20250111063659"", ""headline"": ""Johnson & Johnson Could Serve As High-Yield Bond Alternative"", ""summary"": ""Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest growth expectations.""}, {""date"": ""20250111070506"", ""headline"": ""Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade"", ""summary"": ""Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.""}, {""date"": ""20250112050735"", ""headline"": ""DSTL: One Of The Best Value And Quality ETFs"", ""summary"": ""Distillate U.S. Fundamental Stability & Value ETF focuses on stable stocks with strong cash flow. Read why DSTL is a compelling choice for diversified investors.""}]","{""assetTurnoverTTM"": 0.4994, ""bookValue"": 71490, ""cashRatio"": 0.17966654080801256, ""currentRatio"": 1.1107, ""ebitPerShare"": 1.6002, ""eps"": 1.4125, ""ev"": 372701.7, ""fcfMargin"": 0.2385, ""fcfPerShareTTM"": 8.2437, ""grossMargin"": 0.6844, ""inventoryTurnoverTTM"": 2.3226, ""longtermDebtTotalAsset"": 0.1702, ""longtermDebtTotalCapital"": 0.2835, ""longtermDebtTotalEquity"": 0.4287, ""netDebtToTotalCapital"": 0.2552, ""netDebtToTotalEquity"": 0.386, ""netMargin"": 0.1524, ""operatingMargin"": 0.1726, ""payoutRatioTTM"": 0.8405, ""pb"": 4.8274, ""peTTM"": 24.535, ""pfcfTTM"": 17.3928, ""pretaxMargin"": 0.1726, ""psTTM"": 3.8854, ""ptbv"": 10.1886, ""quickRatio"": 0.7823, ""receivablesTurnoverTTM"": 5.9782, ""roaTTM"": 0.0791, ""roeTTM"": 0.1987, ""roicTTM"": 0.1306, ""rotcTTM"": 0.155, ""salesPerShare"": 9.2709, ""sgaToSale"": 0.3156, ""tangibleBookValue"": 33872, ""totalDebtToEquity"": 0.5124, ""totalDebtToTotalAsset"": 0.2034, ""totalDebtToTotalCapital"": 0.3388, ""totalRatio"": 1.6582, ""period"": ""2024-12-29""}"
10,2025-01-12,140.931884765625,2025-01-19,145.8624267578125,0.03498528385104027,U4,"[{""date"": ""20250112050735"", ""headline"": ""DSTL: One Of The Best Value And Quality ETFs"", ""summary"": ""Distillate U.S. Fundamental Stability & Value ETF focuses on stable stocks with strong cash flow. Read why DSTL is a compelling choice for diversified investors.""}, {""date"": ""20250113055513"", ""headline"": ""Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck"", ""summary"": ""The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027. Explore more details here.""}, {""date"": ""20250113063204"", ""headline"": ""Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc."", ""summary"": ""Acquisition includes CAPLYTA\u00ae , the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in...""}, {""date"": ""20250113072814"", ""headline"": ""J&J: agreement to acquire Intra-Cellular Therapies"", ""summary"": ""Johnson & Johnson reports that it has entered into a definitive agreement to acquire Intra-Cellular Therapies, a biopharmaceutical company focused on central nervous system disorders, for a total net...""}, {""date"": ""20250113073000"", ""headline"": ""How Might Markets React To December Inflation Report"", ""summary"": ""On Wednesday, the Bureau of Labor Statistics will release the consumer price index for December 2024. Check out my thoughts on how markets could react.""}, {""date"": ""20250113080853"", ""headline"": ""Intra-Cellular Therapies rallies as pharma companies buy up smaller rivals"", ""summary"": ""Intra-Cellular Therapies rallies as pharma companies buy up smaller rivals""}, {""date"": ""20250113103144"", ""headline"": ""What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies"", ""summary"": ""Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has blockbuster potential. Learn more on ITCI stock here.""}, {""date"": ""20250113105700"", ""headline"": ""Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal"", ""summary"": ""Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal""}, {""date"": ""20250113121500"", ""headline"": ""Johnson & Johnson makes $15 billion bet on mental-health drugs"", ""summary"": ""Johnson & Johnson makes $15 billion bet on mental-health drugs""}, {""date"": ""20250113123242"", ""headline"": ""J&J to Buy Intra-Cellular for About $14 Billion"", ""summary"": ""-- Johnson & Johnson agreed to acquire Intra-Cellular Therapies , a company focused on treatments for central nervous system disorders, for about $14.6 billion. Katie Greifeld reports on Bloomberg...""}, {""date"": ""20250113125900"", ""headline"": ""UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb"", ""summary"": ""UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb""}, {""date"": ""20250113151300"", ""headline"": ""Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal"", ""summary"": ""Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal""}, {""date"": ""20250113161955"", ""headline"": ""J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug"", ""summary"": ""J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug""}, {""date"": ""20250113162712"", ""headline"": ""Johnson & Johnson (JNJ) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)"", ""summary"": ""Johnson &amp; Johnson (NYSE:JNJ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2024 12:00 PM ETCompany ParticipantsJoaquin Duato - Chairman...""}, {""date"": ""20250113181002"", ""headline"": ""Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025"", ""summary"": ""The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.""}, {""date"": ""20250114060000"", ""headline"": ""7 Blue Chip Dividend Stocks I Used To Build My First $100K Portfolio"", ""summary"": ""Building good financial habits and avoiding debt traps is the hardest part of accumulating your first $100K. Learn how my 7-stock portfolio outperformed S&P 500.""}, {""date"": ""20250114071100"", ""headline"": ""Trump Looms Large Over Stock Markets. Why Chips, Fed Are Just the Beginning and 5 Other Things to Know Today."", ""summary"": ""Trump Looms Large Over Stock Markets. Why Chips, Fed Are Just the Beginning and 5 Other Things to Know Today.""}, {""date"": ""20250114120700"", ""headline"": ""S&P Places Johnson & Johnson on CreditWatch Negative"", ""summary"": ""S&P Places Johnson & Johnson on CreditWatch Negative""}, {""date"": ""20250114145225"", ""headline"": ""Boston Scientific Standing Apart As A Rare Med-Tech Growth Story"", ""summary"": ""Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn more about BSX stock here.""}, {""date"": ""20250114163200"", ""headline"": ""Johnson & Johnson stock underperforms Tuesday when compared to competitors despite daily gains"", ""summary"": ""Johnson & Johnson stock underperforms Tuesday when compared to competitors despite daily gains""}, {""date"": ""20250115072000"", ""headline"": ""ClearBridge Value Fund Q4 2024 Commentary"", ""summary"": ""Strategy outperformed its Russell 1000 Value benchmark during 4Q, as positive contributions from stock selection and sector allocation effects contributed to relative performance.""}, {""date"": ""20250115080113"", ""headline"": ""New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer"", ""summary"": ""Application accepted for U.S. FDA Real-Time Oncology Review based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent1RARITAN, N.J., Jan. 15, 2025...""}, {""date"": ""20250115084136"", ""headline"": ""J&J Initiates Bid for FDA Approval of TAR-200 in Bladder Cancer"", ""summary"": ""By Colin Kellaher Johnson & Johnson has initiated an application seeking Food and Drug Administration approval of its TAR-200 drug-device combination for the treatment of certain patients with...""}, {""date"": ""20250115103516"", ""headline"": ""Johnson & Johnson: FDA to review TAR-200 dossier"", ""summary"": ""Johnson & Johnson announced on Wednesday that the U.S. Food and Drug Administration had agreed to review its application for registration of TAR-200, an experimental treatment for bladder cancer.The...""}, {""date"": ""20250115123957"", ""headline"": ""Buy 3 'Safer' Dividend Kings Of 25 From 53\u00a0For January"", ""summary"": ""53 Dividend Kings offer steady growth across sectors. See why MO, UBSI, and HRL are top picks for January with yields greater than their single-share prices.""}, {""date"": ""20250116053000"", ""headline"": ""Companies From Afar Tap Houston Bankruptcy Court Despite Minimal Local Ties"", ""summary"": ""Companies From Afar Tap Houston Bankruptcy Court Despite Minimal Local Ties""}, {""date"": ""20250116060356"", ""headline"": ""Tempering Positive Sentiment Of AI In Biotech"", ""summary"": ""AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore more details here.""}, {""date"": ""20250116073000"", ""headline"": ""The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems"", ""summary"": """"}, {""date"": ""20250116091206"", ""headline"": ""RYBREVANT\u00ae plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer"", ""summary"": ""Phase 3 MARIPOSA-2 study showed RYBREVANT\u00ae in combination with carboplatin and pemetrexed significantly improved progression-free survival compared to carboplatin and pemetrexed alone.1TORONTO, Jan....""}, {""date"": ""20250116112904"", ""headline"": ""Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves"", ""summary"": ""Johnson & Johnson has underperformed its lerge-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Read my JNJ earnings preview.""}, {""date"": ""20250117095158"", ""headline"": ""Mayar Capital Q2 2024 Letter To Partners"", ""summary"": ""Learn about Mayar Capital's investment management services and Responsible Global Equity Fund performance, along with lessons from historical market...""}, {""date"": ""20250119071853"", ""headline"": ""Wall Street Week Ahead"", ""summary"": ""Stay informed with the latest financial news on Wall Street Breakfast.""}, {""date"": ""20250119072441"", ""headline"": ""The Week Ahead"", ""summary"": ""Get ready for a busy week on Wall Street! Earnings reports from big names like Netflix, Procter & Gamble, and Johnson & Johnson are on the horizon.""}, {""date"": ""20250119165445"", ""headline"": ""Top 4 Immunology Stocks Poised For Growth In 2025"", ""summary"": ""Discover the latest trends and developments in the global immunology drugs market, along with four promising stocks to watch for potential investments.""}]","{""assetTurnoverTTM"": 0.4994, ""bookValue"": 71490, ""cashRatio"": 0.17966654080801256, ""currentRatio"": 1.1107, ""ebitPerShare"": 1.6002, ""eps"": 1.4125, ""ev"": 372701.7, ""fcfMargin"": 0.2385, ""fcfPerShareTTM"": 8.2437, ""grossMargin"": 0.6844, ""inventoryTurnoverTTM"": 2.3226, ""longtermDebtTotalAsset"": 0.1702, ""longtermDebtTotalCapital"": 0.2835, ""longtermDebtTotalEquity"": 0.4287, ""netDebtToTotalCapital"": 0.2552, ""netDebtToTotalEquity"": 0.386, ""netMargin"": 0.1524, ""operatingMargin"": 0.1726, ""payoutRatioTTM"": 0.8405, ""pb"": 4.8274, ""peTTM"": 24.535, ""pfcfTTM"": 17.3928, ""pretaxMargin"": 0.1726, ""psTTM"": 3.8854, ""ptbv"": 10.1886, ""quickRatio"": 0.7823, ""receivablesTurnoverTTM"": 5.9782, ""roaTTM"": 0.0791, ""roeTTM"": 0.1987, ""roicTTM"": 0.1306, ""rotcTTM"": 0.155, ""salesPerShare"": 9.2709, ""sgaToSale"": 0.3156, ""tangibleBookValue"": 33872, ""totalDebtToEquity"": 0.5124, ""totalDebtToTotalAsset"": 0.2034, ""totalDebtToTotalCapital"": 0.3388, ""totalRatio"": 1.6582, ""period"": ""2024-12-29""}"
11,2025-01-19,145.8624267578125,2025-01-26,145.6540985107422,-0.0014282516183294902,D1,"[{""date"": ""20250119071853"", ""headline"": ""Wall Street Week Ahead"", ""summary"": ""Stay informed with the latest financial news on Wall Street Breakfast.""}, {""date"": ""20250119072441"", ""headline"": ""The Week Ahead"", ""summary"": ""Get ready for a busy week on Wall Street! Earnings reports from big names like Netflix, Procter & Gamble, and Johnson & Johnson are on the horizon.""}, {""date"": ""20250119165445"", ""headline"": ""Top 4 Immunology Stocks Poised For Growth In 2025"", ""summary"": ""Discover the latest trends and developments in the global immunology drugs market, along with four promising stocks to watch for potential investments.""}, {""date"": ""20250120050608"", ""headline"": ""High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent"", ""summary"": ""A list of high-quality dividend-growth stocks near 52-week lows, including Merck, Nike, J&J, Pfizer, and more. Click here to find out more about dividend stocks.""}, {""date"": ""20250120054247"", ""headline"": ""IYH: Healthcare Dashboard For January"", ""summary"": ""iShares U.S. Healthcare ETF has higher fees and lower performance. See why IYH is a top choice and learn about 10 cheaper healthcare stocks this January.""}, {""date"": ""20250120150800"", ""headline"": ""Dividend Income: Lanny's December 2024 Summary"", ""summary"": ""Aflac, Grainger, Target, IBM, Johnson & Johnson, Emerson, Archer-Daniels, McDonald\u00e2\u0080\u0099s and T. Rowe Price rounded out the dividend aristocrat list. Click to read.""}, {""date"": ""20250121085817"", ""headline"": ""Johnson & Johnson Gets FDA OK For Spravato as Monotherapy"", ""summary"": ""By Colin Kellaher Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression. J&J on...""}, {""date"": ""20250121091611"", ""headline"": ""J&J: EU approves Lazcluze for lung cancer treatment"", ""summary"": ""J&J announces that the European Commission has approved the marketing authorization of Lazcluze in combination with Rybrevant for the first-line treatment of adult patients with advanced non-small...""}, {""date"": ""20250121094417"", ""headline"": ""J&J: FDA approves Spravato spray for depression"", ""summary"": ""Johnson & Johnson announces that the FDA has approved a supplemental application for Spravato nasal spray, as the first monotherapy for adults with major depression resistant to at least two oral...""}, {""date"": ""20250121104110"", ""headline"": ""Johnson & Johnson : European Commission approves LAZCLUZE\u00ae\u25bc (lazertinib) in combination with RYBREVANT\u00ae\u25bc (amivantamab) for the first line treatment of patients with EGFR mutated advanced non small cell lung cancer"", ""summary"": ""FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY For Immediate Release ...""}, {""date"": ""20250121140900"", ""headline"": ""Dividend Stocks Have Slumped. Why UPS and Others May Bounce Back."", ""summary"": ""Dividend Stocks Have Slumped. Why UPS and Others May Bounce Back.""}, {""date"": ""20250122001804"", ""headline"": ""FDA approves Spravato, first monotherapy nasal spray to treat depression"", ""summary"": ""The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.Johnson & Johnson's Spravato has been approved to treat a major depressive...""}, {""date"": ""20250122062103"", ""headline"": ""Johnson & Johnson Reports Q4 and Full-Year 2024 Results"", ""summary"": ""2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7%*2024 Fourth-Quarter Earnings per share of $1.41 and...""}, {""date"": ""20250122063207"", ""headline"": ""Johnson & Johnson : Fourth Quarter 2024 Earnings Presentation"", ""summary"": ""4th Quarter 2024 Earnings Call January 22, 2025 Cautionary note on Forward-looking statements This...""}, {""date"": ""20250122074414"", ""headline"": ""Johnson & Johnson: EPS down 11% in Q4"", ""summary"": ""Johnson & Johnson reports adjusted EPS for the last three months of 2024 down 10.9% at $2.04, a level roughly in line with expectations, although burdened to the tune of 22 cents by IPR&D charges...""}, {""date"": ""20250122074805"", ""headline"": ""Johnson & Johnson : Fourth Quarter 2024 4Q24 Other Financial Disclosures"", ""summary"": ""Fourth Quarter 2024 Other Financial Disclosures Table of Contents Table 1: Sales by Segment ...""}, {""date"": ""20250122090900"", ""headline"": ""Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth"", ""summary"": ""Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth""}, {""date"": ""20250122094715"", ""headline"": ""Johnson & Johnson 2024 Q4 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Johnson &amp; Johnson in conjunction with their 2024 Q4 earnings call.""}, {""date"": ""20250122103131"", ""headline"": ""Johnson & Johnson - European Commission approves LAZCLUZE in combination with RYBREVANT for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer"", ""summary"": ""BEERSE, BELGIUM - Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission has approved a Marketing Authorisation for LAZCLUZE , in combination with...""}, {""date"": ""20250122103132"", ""headline"": ""Johnson & Johnson - SPRAVATO approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression"", ""summary"": ""Titusville, New Jersey - Johnson & Johnson announced today the U.S. Food and Drug Administration approval of a supplemental New Drug Application for SPRAVATO CIII nasal spray, making this...""}, {""date"": ""20250122114311"", ""headline"": ""Why the Dow is lagging the S&P 500 and the Nasdaq"", ""summary"": ""Why the Dow is lagging the S&P 500 and the Nasdaq""}, {""date"": ""20250122114500"", ""headline"": ""Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance"", ""summary"": ""Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance""}, {""date"": ""20250122120931"", ""headline"": ""Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript"", ""summary"": ""Johnson &amp; Johnson (NYSE:JNJ) Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, Investor...""}, {""date"": ""20250122121500"", ""headline"": ""Bert's December 2024 Dividend Income Summary"", ""summary"": ""December always has the highest allocation of fund payments due to the capital gains distributions. Click to read.""}, {""date"": ""20250122122436"", ""headline"": ""Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing"", ""summary"": ""Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.""}, {""date"": ""20250122125108"", ""headline"": ""Stocks of companies reporting earnings are providing a net 50-point boost to the Dow"", ""summary"": ""Stocks of companies reporting earnings are providing a net 50-point boost to the Dow""}, {""date"": ""20250122143107"", ""headline"": ""FDA approves innovative monotherapy for treatment-resistant depression"", ""summary"": ""The US Food and Drug Administration has approved the first monotherapy for adults with treatment-resistant depression. Johnson & Johnson's SPRAVATO \u00ae CIII nasal spray is indicated for major...""}, {""date"": ""20250122160000"", ""headline"": ""Wall Street Lunch: AI Project Stargate A Go"", ""summary"": ""Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data centers in the U.S.""}, {""date"": ""20250122160906"", ""headline"": ""MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value"", ""summary"": ""MeiraGTx's financials show $125 million in cash, but additional funding will be needed within the next 12 months. Click for my MGTX stock update.""}, {""date"": ""20250122163329"", ""headline"": ""J&J Skids After Dow Giant Beat Earnings Views, But 'Prudent' Guidance Disappoints"", ""summary"": ""J&J Skids After Dow Giant Beat Earnings Views, But 'Prudent' Guidance Disappoints""}, {""date"": ""20250122163900"", ""headline"": ""These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More"", ""summary"": ""These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More""}, {""date"": ""20250122170000"", ""headline"": ""Health Care Roundup: Market Talk"", ""summary"": ""Health Care Roundup: Market Talk""}, {""date"": ""20250122180000"", ""headline"": ""How To Build A $100,000 Dividend Portfolio: SCHD As The Core For Income And Growth"", ""summary"": ""SCHD ETF effectively combines dividend income and dividend growth, while offering investors a reduced Expense Ratio. Click here to read why SCHD is a Strong Buy.""}, {""date"": ""20250123053605"", ""headline"": ""Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology"", ""summary"": ""The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+Nipocalimab demonstrated a sustained reduction in...""}, {""date"": ""20250123054916"", ""headline"": ""Johnson & Johnson reports Q4 2024 and Full-Year 2024 results"", ""summary"": ""New Brunswick - Johnson & Johnson today announced results for fourth-quarter and full year 2024.'2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating...""}, {""date"": ""20250123080131"", ""headline"": ""Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colour"", ""summary"": ""Underscores the urgent need for improved diagnosis and clinical management of psoriasis in patients with skin of colour and enhanced treatment standards ...""}, {""date"": ""20250123090143"", ""headline"": ""Johnson & Johnson exceeds expectations for fourth quarter"", ""summary"": ""Copyright \u00a9 BusinessAMBE 2023Key takeawaysJohnson & Johnson reported $22.5 billion in revenue and adjusted earnings per share of $2.04.Darzalex sales increased 20 percent to $3.08...""}, {""date"": ""20250123094314"", ""headline"": ""J&J: positive results in generalized myasthenia gravis"", ""summary"": ""Johnson & Johnson reports that The Lancet Neurology has published the results of a Phase 3 study of nipocalimab, evaluated in a large population of antibody-positive adults with generalized...""}, {""date"": ""20250123094600"", ""headline"": ""JPMorgan Chase, Goldman Sachs share gains lead Dow's 125-point jump"", ""summary"": ""JPMorgan Chase, Goldman Sachs share gains lead Dow's 125-point jump""}, {""date"": ""20250123112300"", ""headline"": ""UnitedHealth, Caterpillar share gains contribute to Dow's 250-point jump"", ""summary"": ""UnitedHealth, Caterpillar share gains contribute to Dow's 250-point jump""}, {""date"": ""20250123145520"", ""headline"": ""Kura Oncology: Sentiment Is Too Negative"", ""summary"": ""Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive acquisition target despite its promising AML drug candidate ziftomenib.""}, {""date"": ""20250124020100"", ""headline"": ""Disasters Spawn New Businesses. The California Wildfires Will Do the Same."", ""summary"": ""Disasters Spawn New Businesses. The California Wildfires Will Do the Same.""}, {""date"": ""20250124031425"", ""headline"": ""What Can The Dividend Kings Deliver In 2025?"", ""summary"": ""The Dividend Kings underperformed in 2024. Read here to know about the top 18 most opportune Dividend Kings based on valuation and total return.""}, {""date"": ""20250124164015"", ""headline"": ""Johnson & Johnson : Fourth Quarter 2024 2024 Fourth-Quarter Earnings Transcript"", ""summary"": ""REFINITIV STREETEVENTS EDITED TRANSCRIPT JNJ.N - Q4 2024 Johnson & Johnson Earnings Call EVENT DATE/TIME: JANUARY...""}]",{}
12,2025-01-26,145.6540985107422,2025-02-02,150.94175720214844,0.03630284863570998,U4,"[{""date"": ""20250127122800"", ""headline"": ""Salesforce, Johnson & Johnson share gains contribute to Dow's nearly 150-point jump"", ""summary"": ""Salesforce, Johnson & Johnson share gains contribute to Dow's nearly 150-point jump""}, {""date"": ""20250127124902"", ""headline"": ""Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?"", ""summary"": ""Stryker Corporation's innovation and market leadership justify a premium. See why SYK stock is a solid hold with long-term growth potential despite high valuations.""}, {""date"": ""20250127133000"", ""headline"": ""Liquidity Up, Markets Up, Liquidity Down, Markets Down"", ""summary"": ""Why Kirk Spano thinks there is potential for dislocations in the economy and markets.""}, {""date"": ""20250127142600"", ""headline"": ""Dow up 265 points on gains in shares of Salesforce, Johnson & Johnson"", ""summary"": ""Dow up 265 points on gains in shares of Salesforce, Johnson & Johnson""}, {""date"": ""20250128125105"", ""headline"": ""Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ"", ""summary"": ""NEW YORK, Jan. 28, 2025 /PRNewswire/ --\u00a0Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson\u00a0\u00a0.\u00a0Such investors are advised to contact Danielle Peyton at...""}, {""date"": ""20250128145000"", ""headline"": ""Franklin Income Fund Q4 2024 Commentary"", ""summary"": ""Franklin Income Fund fared better than Blended 50% MSCI USA High Dividend Yield Index + 25% Bloomberg High Yield Very Liquid Index + 25% Bloomberg US Aggregate Index.""}, {""date"": ""20250129070145"", ""headline"": ""Cilta-cel: A new era in multiple myeloma treatment"", ""summary"": ""Multiple myeloma is a rare and aggressive blood cancer that originates in plasma cells, a type of white blood cell in the bone marrow. However, in multiple myeloma, the plasma cells become cancerous...""}, {""date"": ""20250129083752"", ""headline"": ""Smith & Nephew Getting No Credit For Self-Improvement Efforts ... But Should It?"", ""summary"": ""Smith & Nephew's stock underperformance due to market share losses & pricing pressures in China.""}, {""date"": ""20250129130500"", ""headline"": ""Franklin Managed Income Fund Q4 2024 Commentary"", ""summary"": ""During the quarter, the Fed lowered the federal funds target rate by 25 basis points in November and another 25 bps in December. Read more here.""}, {""date"": ""20250129180000"", ""headline"": ""How To Strategically Allocate $25,000: Positioning Your Dividend Portfolio For 2025"", ""summary"": ""Maximize your dividend portfolio potential with strategic allocations for 2025.""}, {""date"": ""20250130170315"", ""headline"": ""Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)"", ""summary"": ""Discover why Johnson & Johnson is a top stock pick for income investors in 2025 with strong sales growth and promising earnings outlook.""}, {""date"": ""20250130231948"", ""headline"": ""Tracking Yacktman Asset Management Portfolio - Q4 2024 Update"", ""summary"": ""Read here for an update on Yacktman Asset Management's portfolio changes, top holdings, and performance compared to market indexes.""}, {""date"": ""20250201063848"", ""headline"": ""What Moved Markets This Week"", ""summary"": ""U.S. stocks end a tough week as DeepSeek rattles tech stocks and the Fed Holds interest rates steady. Read more about this week's major events on Wall Street.""}, {""date"": ""20250202050529"", ""headline"": ""ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data"", ""summary"": ""ORIC's ORIC-533 was promising but failed in trials, leaving ORIC-114 and ORIC-944 as key pipeline assets. Read why I am neutral on ORIC stock.""}]",{}
13,2025-02-02,150.94175720214844,2025-02-09,151.904052734375,0.006375277127175671,U1,"[{""date"": ""20250202050529"", ""headline"": ""ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data"", ""summary"": ""ORIC's ORIC-533 was promising but failed in trials, leaving ORIC-114 and ORIC-944 as key pipeline assets. Read why I am neutral on ORIC stock.""}, {""date"": ""20250203050818"", ""headline"": ""Johnson & Johnson : CHMP recommends subcutaneous RYBREVANT\u00ae\u25bc (amivantamab) for the treatment of patients with advanced EGFR mutated non small cell lung cancer"", ""summary"": ""Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended an extension of...""}, {""date"": ""20250203075517"", ""headline"": ""J&J: CHMP gives the green light for subcutaneous Rybrevant"", ""summary"": ""Janssen-Cilag International NV announces that the Committee for Medicinal Products for Human Use of the EMA has recommended the extension of the marketing authorization for the subcutaneous...""}, {""date"": ""20250203085100"", ""headline"": ""You Deserve Reliable Income: 2 Undervalued Dividends For Long-Term Growth"", ""summary"": ""UPS and JNJ present strong dividends and attractive valuations. See why these durable companies are great for a buy-and-hold strategy with long-term growth.""}, {""date"": ""20250204051009"", ""headline"": ""Federal District Court Dismisses Another Case Regarding The Cost Of Prescription Drug Coverage"", ""summary"": ""On January 24, 2025, the United States District Court for the District of New Jersey dismissed a putative ERISA class action lawsuit in a much-followed case involving Johnson & Johnson in which the...""}, {""date"": ""20250204141100"", ""headline"": ""Healthcare Stocks Have Gotten a Boost. Now Comes the Hard Part."", ""summary"": ""Healthcare Stocks Have Gotten a Boost. Now Comes the Hard Part.""}, {""date"": ""20250205015500"", ""headline"": ""J.P. Morgan Healthcare Conference 2025: Healthcare's Roadmap For The Year Ahead"", ""summary"": ""Major deals, including Johnson & Johnson\u00e2\u0080\u0099s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly $1T in industry financial capacity. Read more here.""}, {""date"": ""20250205081500"", ""headline"": ""Franklin Income SMA Q4 2024 Commentary"", ""summary"": ""US stocks collectively rose in the fourth quarter of 2024 despite retreating in December. Read more here.""}, {""date"": ""20250205090600"", ""headline"": ""Starboard Launches Proxy Fight at Kenvue"", ""summary"": ""Starboard Launches Proxy Fight at Kenvue""}, {""date"": ""20250205140000"", ""headline"": ""My Top 5 Dividend-Paying Buy-And-Hold Stocks For 2025"", ""summary"": """"}, {""date"": ""20250206093500"", ""headline"": ""Franklin Equity Income Fund Q4 2024 Commentary"", ""summary"": ""US stocks collectively rose in the fourth quarter of 2024, with the S&P 500 Index, Dow Jones Industrial Average and NASDAQ Composite Index reaching new record highs.""}, {""date"": ""20250207062432"", ""headline"": ""3 Ideal Buys In 63 January Fortune 500 Industry Leaders Wherein 57 Paid Dividends And 39 Tested As 'Safer'"", ""summary"": ""January\u00e2\u0080\u0099s top-rated Fortune 500 stocks show high yields and growth. Learn why MO, ET, and T are safer buys based on dividends and long-term performance.""}, {""date"": ""20250207152459"", ""headline"": ""Our Real-Life Market-Beating U.S. Stock Portfolio, Ten Years After"", ""summary"": ""Discover the successful decade-long journey of a stock portfolio focusing on dividend growth companies, outperforming the S&P 500. Find out the lessons I've learned.""}, {""date"": ""20250208075421"", ""headline"": ""One 'Safer' Buy In 10 February Dogs Of The Dow"", ""summary"": ""Verizon's dividend yield and Merck\u00e2\u0080\u0099s growth lead the Dow Dogs. Read why they\u00e2\u0080\u0099re set for solid returns, with other top picks closely following in February 2026.""}]",{}
14,2025-02-09,151.904052734375,2025-02-16,154.91000366210938,0.019788484070208945,U2,"[{""date"": ""20250210000331"", ""headline"": ""Kenvue: An Intriguing Turnaround"", ""summary"": ""Kenvue's improvements in marketing and management could drive future growth. Read why there is potential for a turnaround for KVUE stock.""}, {""date"": ""20250210010000"", ""headline"": ""Tweedy, Browne Fund Q4 2024 Commentary"", ""summary"": ""Setting aside a rather brief hiccup mid-quarter, the bull market in global equities continued in force during Q4 2024. Click here to read the full commentary. ""}, {""date"": ""20250210054700"", ""headline"": ""Fidelity Balanced Fund Q4 2024 Review"", ""summary"": ""For the fourth quarter of 2024, the fund's Retail Class shares gained 0.59%, topping the 0.21% advance of the Fidelity Balanced Hybrid Composite Index.""}, {""date"": ""20250210071800"", ""headline"": ""Fidelity Strategic Dividend & Income Fund Q4 2024 Review"", ""summary"": ""Our investment approach aims to offer a well-diversified strategy with the potential to deliver strong income regardless of the interest-rate environment. Read more here.""}, {""date"": ""20250211014000"", ""headline"": ""Steady M&A Deals To Begin 2025, Disappointing IPOs So Far"", ""summary"": ""A few notable health care deals along with M&A in the AI-adjacent and reshoring themes occurred in January. Read more here.""}, {""date"": ""20250211073000"", ""headline"": ""The Lazy Investor's Dividend Jackpot: Stress-Free Income For Life"", ""summary"": ""Dividend growth investing is a proven, low-risk strategy for building wealth. Check out my four dividend growth stock picks to build wealth.""}, {""date"": ""20250211114400"", ""headline"": ""Invesco Diversified Dividend Fund Q4 2024 Commentary"", ""summary"": ""Fund outperformed the Russell 1000 Value Index primarily due to strong stock selection in information technology, while health care, particularly managed health care and pharma detracted.""}, {""date"": ""20250211134100"", ""headline"": ""Invesco Dividend Income Fund Q4 2024 Commentary"", ""summary"": ""The fund is balanced across sectors and industries, with a focus on long-term growth areas and companies with sustainable free cash flow and healthy balance sheets.""}, {""date"": ""20250211172043"", ""headline"": ""Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade"", ""summary"": """"}, {""date"": ""20250211215000"", ""headline"": ""Invesco Growth And Income Fund Q4 2024 Commentary"", ""summary"": ""Stock selection in the financials, consumer discretionary, communication services and information technology sectors drove the fund\u00e2\u0080\u0099s relative outperformance.""}, {""date"": ""20250212162606"", ""headline"": ""IGA: Good Diversification And Fully-Covered Distribution (Rating Upgrade)"", ""summary"": ""Voya Global Advantage and Premium Opportunity Fund has a 10.74% yield, diversification benefits, and well-covered distributions. Click for my IGA CEF update.""}, {""date"": ""20250212204000"", ""headline"": ""Janus Henderson Global Life Sciences Fund Q4 2024 Commentary"", ""summary"": ""The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary. ""}, {""date"": ""20250212221529"", ""headline"": ""Tracking Tweedy Browne Portfolio - Q4 2024 Update"", ""summary"": ""Tweedy Browne\u00e2\u0080\u0099s 13F portfolio value decreased from $2.10B to $1.48B. Click here to read more about the trades and holdings of the portfolio.""}, {""date"": ""20250213140400"", ""headline"": ""Cisco, NVIDIA Corp. share gains lead Dow's nearly 250-point jump"", ""summary"": ""Cisco, NVIDIA Corp. share gains lead Dow's nearly 250-point jump""}, {""date"": ""20250213174928"", ""headline"": ""Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain"", ""summary"": ""Kiniksa Pharmaceuticals stock is attractive because it trades near 52-week lows, and its marketed drug gains traction. Click to find out why KNSA is a Hold.""}, {""date"": ""20250213205800"", ""headline"": ""Janus Henderson Global Life Sciences Diversified ADR Managed Account Q4 2024 Commentary"", ""summary"": ""The Portfolio returned -10.75% (gross) and the MSCI World Health Care IndexSM returned -11.32%. Read more here.""}, {""date"": ""20250213224026"", ""headline"": ""Tracking Jeremy Grantham's GMO Capital Portfolio - Q4 2024 Update"", ""summary"": ""GMO's portfolio update highlights key stock adjustments and forecasts a promising 9.6% return for International Deep Value assets. See more here.""}, {""date"": ""20250214080000"", ""headline"": ""J&J\u2019s High Hopes for Heart-Rhythm Device Grounded by Safety Concerns"", ""summary"": ""J&J\u2019s High Hopes for Heart-Rhythm Device Grounded by Safety Concerns""}, {""date"": ""20250215110000"", ""headline"": ""Walmart, Alibaba, Medtronic To Reports Earnings During Holiday-Shortened Week"", ""summary"": ""Holiday shortens this week's earnings reports. U.S. housing data is to be released this week, with housing starts on Wed., and existing home sales on Friday.""}, {""date"": ""20250216011101"", ""headline"": ""IXJ: Healthcare Sector\u00a0Dashboard For February"", ""summary"": ""The healthcare sector is currently overvalued by about 13% relative to 11-year averages. Check out the top-down analysis of the healthcare sector.""}, {""date"": ""20250216070537"", ""headline"": ""Globus Medical: Some Caution After Its Deal For Nevro"", ""summary"": ""Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read why I'm neutral on GMED stock.""}]",{}
15,2025-02-16,154.91000366210938,2025-02-23,162.3000030517578,0.04770511403361377,U5,"[{""date"": ""20250216011101"", ""headline"": ""IXJ: Healthcare Sector\u00a0Dashboard For February"", ""summary"": ""The healthcare sector is currently overvalued by about 13% relative to 11-year averages. Check out the top-down analysis of the healthcare sector.""}, {""date"": ""20250216070537"", ""headline"": ""Globus Medical: Some Caution After Its Deal For Nevro"", ""summary"": ""Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read why I'm neutral on GMED stock.""}, {""date"": ""20250217092300"", ""headline"": ""Wall Street Brunch: Apple And Walmart Dominate Short Week"", ""summary"": ""New Apple product seen, but no livestream keynote. Walmart commentary on tariff impact expected. Traders eye FOMC minutes.""}, {""date"": ""20250217140000"", ""headline"": ""Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025"", ""summary"": ""Kenvue, spun off from J&J, offers long-term dividend potential with strong brands like Tylenol and Listerine. Click here to read an analysis of KVUE stock now.""}, {""date"": ""20250218021653"", ""headline"": ""Johnson & Johnson: Rich History Of Excellence Poised To Endure"", ""summary"": ""Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a Strong Buy rating for JNJ stock.""}, {""date"": ""20250218022553"", ""headline"": ""Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon"", ""summary"": ""Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion in cash. Read more here.""}, {""date"": ""20250218080000"", ""headline"": ""American Century Equity Income Fund Q4 2024 Commentary"", ""summary"": ""Growth stocks outpaced their value counterparts during the quarter, even as some investors sought lower-volatility positions. Read more here.""}, {""date"": ""20250218172200"", ""headline"": ""Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan"", ""summary"": ""Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan""}, {""date"": ""20250219043000"", ""headline"": ""January's $10 Billion M&A Deals And Bids Span Sectors"", ""summary"": ""The January megadeals included transactions in the energy, financials, pharmaceuticals and materials sectors, signaling a broad-based large-cap M&A market appetite.""}, {""date"": ""20250219081000"", ""headline"": ""My Dividend Stock Portfolio: New January Dividend Record - 100 Holdings With 14 Buys"", ""summary"": ""January hits new highs with $814 in dividend income, up 21% Y/Y. See how BDC investments drive growth toward $11,000 annual dividends.""}, {""date"": ""20250219122610"", ""headline"": ""AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant"", ""summary"": ""Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each healthcare company.""}, {""date"": ""20250220133200"", ""headline"": ""Madison Dividend Income Fund Q4 2024 Investment Strategy Letter"", ""summary"": ""For the full year, the Fund returned +7.7%, which compared to the S&P 500, Russell 1000 Value and Lipper Equity Income peer group returns of +25.0%, +14.4%, and +14.1% respectively.""}, {""date"": ""20250220222629"", ""headline"": ""Tracking Ray Dalio's Bridgewater Associates 13F Portfolio - Q4 2024 Update"", ""summary"": ""Bridgewater Associates' Q3 moves: Portfolio value rises to $21.81B. Notable stake reductions were seen in GOOG, NVDA, META, MSFT, and AMZN. See more here.""}, {""date"": ""20250221054500"", ""headline"": ""Allspring Growth Fund Q4 2024 Commentary"", ""summary"": ""The Allspring Growth Fund underperformed the Russell 3000 Growth Index during the quarter that ended December 31, 2024. Click here to read the full commentary. ""}, {""date"": ""20250221070107"", ""headline"": ""TREMFYA\u00ae (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis"", ""summary"": ""Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patientsThe only SC induction data for an IL-23 inhibitor show statistically significant and...""}, {""date"": ""20250221125243"", ""headline"": ""Is Johnson & Johnson (JNJ) the Best Non-Tech Stock to Buy Now for Long Term?"", ""summary"": ""We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other non-tech stocks. Investing in non-technology stocks offers a range of benefits that can enhance an investor\u2019s portfolio, providing diversification, [\u2026]""}, {""date"": ""20250221151100"", ""headline"": ""American Century Value Fund Q4 2024 Commentary"", ""summary"": ""U.S. equities broadly advanced during the quarter, despite a pullback in December. Read more here.""}, {""date"": ""20250221163025"", ""headline"": ""Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue?"", ""summary"": ""Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""20250222110014"", ""headline"": ""Is Johnson & Johnson's (NYSE:JNJ) Recent Stock Performance Influenced By Its Fundamentals In Any Way?"", ""summary"": ""Most readers would already be aware that Johnson & Johnson's (NYSE:JNJ) stock increased significantly by 11% over the...""}, {""date"": ""20250222200000"", ""headline"": ""European Banks Swarm Dollar Market For AT1 Debt: Credit Weekly"", ""summary"": ""(Bloomberg) -- European banks have turned to the US dollar market to sell almost $8 billion of bonds that help them boost capital levels. Investors hunting for higher coupons want even more.Most Read from BloombergTrump Targets $128 Billion California High-Speed Rail ProjectTrump Asserts Power Over NYC, Proclaims \u2018Long Live the King\u2019Trump to Halt NY Congestion Pricing by Terminating ApprovalAirbnb Billionaire Offers Pre-Fab Homes for LA Fire VictimsSorry, Kids: Disney\u2019s New York Headquarters Is""}, {""date"": ""20250223115222"", ""headline"": ""Why AbbVie Remains A Strong Buy For Long-Term Investors"", ""summary"": ""Discover why AbbVie stands out for long-term investors with strong growth in Skyrizi & Qulipta sales.""}, {""date"": ""20250223200204"", ""headline"": ""Johnson & Johnson (JNJ): Among the Best Performing Dow Stocks So Far in 2025"", ""summary"": ""We recently published a list of 11 Best Performing Dow Stocks So Far in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best performing Dow stocks so far in 2025. The Dow is a renowned and significant stock market index that measures the [\u2026]""}]",{}
16,2025-02-23,162.3000030517578,2025-03-02,165.02000427246094,0.016759095314592853,U2,"[{""date"": ""20250223115222"", ""headline"": ""Why AbbVie Remains A Strong Buy For Long-Term Investors"", ""summary"": ""Discover why AbbVie stands out for long-term investors with strong growth in Skyrizi & Qulipta sales.""}, {""date"": ""20250223200204"", ""headline"": ""Johnson & Johnson (JNJ): Among the Best Performing Dow Stocks So Far in 2025"", ""summary"": ""We recently published a list of 11 Best Performing Dow Stocks So Far in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best performing Dow stocks so far in 2025. The Dow is a renowned and significant stock market index that measures the [\u2026]""}, {""date"": ""20250224053500"", ""headline"": ""Columbia Dividend Income Fund Q4 2024 Commentary"", ""summary"": ""Institutional Class shares of Columbia Dividend Income Fund returned -1.34% for Q4 2024. Click here to read the full commentary. ""}, {""date"": ""20250224062400"", ""headline"": ""Hartford Balanced Income Fund Q4 2024 Commentary"", ""summary"": ""Hartford Balanced Income Fund (I Share) underperformed its benchmark. Global fixed-income markets generated negative total returns during the fourth quarter.""}, {""date"": ""20250224102319"", ""headline"": ""Johnson & Johnson MedTech Celebrates Inaugural National Heart Recovery Awareness Day"", ""summary"": ""DANVERS, Mass- Johnson & Johnson MedTech, the global leader in heart recovery, is proud to celebrate the inaugural National Heart Recovery Awareness Day today, February 20. Recognized through a U.S....""}, {""date"": ""20250224110819"", ""headline"": ""TREMFYA (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis"", ""summary"": ""SPRING HOUSE, Pa. - Johnson & Johnson today announced data from the Phase 3 ASTRO study of TREMFYA subcutaneous induction therapy in adults with moderately to severely active ulcerative colitis at...""}, {""date"": ""20250224123000"", ""headline"": ""2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream"", ""summary"": ""A higher dividend yield is nice because it allows you to collect more dividend income on every dollar you invest in a stock.  Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are two very healthy, high-yielding dividend stocks.  Medtronic currently has a 3.1% dividend yield.""}, {""date"": ""20250224134649"", ""headline"": ""LVHD: Seeking Low Volatility In High Dividends With Average Result"", ""summary"": ""Franklin LVHD ETF: Explore a 111-stock portfolio with value traits focusing on utilities and staples.""}, {""date"": ""20250224142746"", ""headline"": ""Is Johnson & Johnson (JNJ) the Best DRIP Stock to Own Now?"", ""summary"": ""We recently published a list of 10 Best DRIP Stocks To Own Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best DRIP stocks to own now. Dividend investing is often regarded as a strategy that rewards patience, as it tends to generate stronger [\u2026]""}, {""date"": ""20250224143000"", ""headline"": ""5 Stocks in the Dow ETF That Survived the Worst Week Since October"", ""summary"": ""Dow Jones witnesses its biggest weekly drop since October amid renewed concerns about economic growth. Let's look at the stocks that survived.""}, {""date"": ""20250224162400"", ""headline"": ""ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales"", ""summary"": ""Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.""}, {""date"": ""20250224222300"", ""headline"": ""Hartford Equity Income Fund Q4 2024 Commentary"", ""summary"": ""Hartford Equity Income Fund (I share) underperformed the Russell 1000 Value Index during the quarter. Read more here.""}, {""date"": ""20250225095400"", ""headline"": ""Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage."", ""summary"": ""Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.""}, {""date"": ""20250225113856"", ""headline"": ""J&J\u2019s potential neurovascular exit: implications for market dynamics"", ""summary"": ""The neurovascular market, estimated at $4.2bn in 2024 by GlobalData, is becoming increasingly specialised and competitive.""}, {""date"": ""20250225144347"", ""headline"": ""Johnson & Johnson (JNJ) Ranked 4th Best S&P 500 Dividend Aristocrat According to Hedge Funds"", ""summary"": ""We recently published a list of S&P 500 Dividend Aristocrats List: Sorted By Hedge Fund Sentiment. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other S&P 500 dividend aristocrats sorted by hedge fund sentiment. Dividend Aristocrats are companies that have consistently increased their dividend payments [\u2026]""}, {""date"": ""20250225161600"", ""headline"": ""Healthcare Stocks Should Be Hurting. How the Sector Became This Year\u2019s Top Performer."", ""summary"": ""Healthcare Stocks Should Be Hurting. How the Sector Became This Year\u2019s Top Performer.""}, {""date"": ""20250225224531"", ""headline"": ""Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note"", ""summary"": ""In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day.""}, {""date"": ""20250225234232"", ""headline"": ""J&J sues Samsung Bioepis over \u2018surreptitious\u2019 breach of Stelara biosimilar contract"", ""summary"": ""Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous settlement.""}, {""date"": ""20250226091544"", ""headline"": ""Merck's Oncology Strength: Beating Wall Street Again"", ""summary"": ""Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.""}, {""date"": ""20250226093916"", ""headline"": ""Is Johnson & Johnson (JNJ) the Best Retirement Stock to Buy According to Hedge Funds?"", ""summary"": ""We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best retirement stocks to buy according to hedge funds. After much suspense, the US Federal Reserve finally began cutting interest [\u2026]""}, {""date"": ""20250226154812"", ""headline"": ""Johnson & Johnson (JNJ): Among the Top Dividend Stocks to Buy According to Hedge Funds"", ""summary"": ""We recently compiled a list of the Top 10 Dividend Stocks To Buy According To Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other dividend stocks. The sustained high inflation over the past two years has resulted in increased borrowing costs, posing difficulties [\u2026]""}, {""date"": ""20250226164507"", ""headline"": ""Johnson & Johnson (JNJ) Could Be a Great Choice"", ""summary"": ""Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.""}, {""date"": ""20250226190701"", ""headline"": ""2025 Dividend Kings - Off To A Strong Start"", ""summary"": ""The Dividend Kings are outperforming the S&P 500 in 2025, up 4% YTD versus 1.39% for SPY. Check out the list of dividend kings that are attractive.""}, {""date"": ""20250226203734"", ""headline"": ""Is Johnson & Johnson (JNJ) the Cheap Global Stock to Buy Right Now?"", ""summary"": ""We recently published a list of 7 Cheap Global Stocks to Buy Right Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other cheap global stocks to buy right now. The geopolitical landscape has drastically changed since the beginning of the decade, with the COVID-19 [\u2026]""}, {""date"": ""20250226211200"", ""headline"": ""Supreme Court Signals Minority Groups Get No Edge in Bias Suits"", ""summary"": ""WASHINGTON\u2014Amid a MAGA-led backlash to diversity, equity and inclusion policies, the Supreme Court signaled it would rule that white people and members of other majority groups who file reverse-discrimination lawsuits shouldn\u2019t face tougher legal scrutiny than Black and other minority employees with bias claims.  Wednesday\u2019s case came from Ohio, where  Marlean Ames  claims the state agency where she works denied her a promotion and then demoted her because she is heterosexual, instead giving both her old job and the one she had sought to gay people.  A federal appeals court in Cincinnati threw out Ames\u2019s lawsuit, finding that she failed to show the \u201cbackground circumstances\u201d suggesting the employer was hostile to straight people\u2014a threshold step that wouldn\u2019t have been required had a gay employee claimed discrimination.""}, {""date"": ""20250227100934"", ""headline"": ""Why Novartis Remains A 'Buy' After Beating Expectations Again"", ""summary"": ""Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read why I maintain my Buy rating on NVS.""}, {""date"": ""20250227124514"", ""headline"": ""Atai: Following The Path That Spravato Laid And Moving Beyond It"", ""summary"": ""Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.""}, {""date"": ""20250227133833"", ""headline"": ""Johnson & Johnson (JNJ): One of the Best Vaccine Stocks to Buy According to Hedge Funds"", ""summary"": ""We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other best vaccine stocks to buy now. What Will Trump\u2019s Tariffs Mean for the Pharma Industry? On February 24, [\u2026]""}, {""date"": ""20250227140019"", ""headline"": ""Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""20250227180000"", ""headline"": ""Building A $1,000,000 Dividend Portfolio: A Strategy For Growth, Income And Risk Management"", ""summary"": ""A high net worth dividend portfolio should prioritize capital preservation. Read more about an investment approach that offers diversification and helps generate extra income.""}, {""date"": ""20250228093947"", ""headline"": ""EMA's CHMP Adopts Stelara Extension For Children With Crohn'S Disease Weighing At Least 40kg"", ""summary"": ""EMA's CHMP: * ADOPTED EXTENSION TO EXISTING INDICATION TO EXTEND USE OFSTELARA TO CHILDREN WITH CROHN\u2019S DISEASE WEIGHING AT LEAST 40 KGSource text:Further company coverage: ...""}, {""date"": ""20250301002148"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of March 2"", ""summary"": ""Read here for key dividend updates for Dividend Champions, Contenders, and Challengers. Learn about changes, ex-dividend dates, & payment schedules.""}, {""date"": ""20250301080000"", ""headline"": ""5 Relatively Secure And Cheap Dividend Stocks, Yields Upto 8% (March 2025)"", ""summary"": ""Discover 5 large-cap, dividend-paying stocks trading at significant discounts. Explore conservative picks plus options with yields up to 8%.""}, {""date"": ""20250302162900"", ""headline"": ""J&J\u2019s New Talc Tort Trial"", ""summary"": ""J&J\u2019s New Talc Tort Trial""}]",{}
17,2025-03-02,165.02000427246094,2025-03-09,166.69000244140625,0.010119974098340423,U2,"[{""date"": ""20250302162900"", ""headline"": ""J&J\u2019s New Talc Tort Trial"", ""summary"": ""J&J\u2019s New Talc Tort Trial""}, {""date"": ""20250303105920"", ""headline"": ""Johnson & Johnson's DARZALEX subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility"", ""summary"": ""BEERSE, BELGIUM - Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has...""}, {""date"": ""20250303135100"", ""headline"": ""Wall Street Lunch: Ghost Of Stagflation Alarms Investors"", ""summary"": ""The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board following the weekend surge in crypto.""}, {""date"": ""20250304081905"", ""headline"": ""Johnson & Johnson : Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult to Cross Calcified Lesions"", ""summary"": ""SANTA CLARA, Calif. - March 4, 2025 - Today, Shockwave Medical, Inc., part of Johnson & Johnson MedTech and a global leader in the field of circulatory restoration, announced the U.S. launch of its...""}, {""date"": ""20250304145603"", ""headline"": ""Dogs Of The Dow Chase A \""Safer\"" Buy For March"", ""summary"": ""My monthly update and commentary on the top dividend stock picks from the Dogs Of The Dow, March 2025 edition. Click here to read more about Dogs of the Dow.""}, {""date"": ""20250304151505"", ""headline"": ""Johnson & Johnson (JNJ) Presents at 45th Annual TD Cowen Healthcare Conference (Transcript)"", ""summary"": ""Johnson &amp; Johnson (NYSE:JNJ) 45th Annual TD Cowen Healthcare Conference March 4, 2025 11:10 AM ETCompany ParticipantsTim Schmid - Executive Vice...""}, {""date"": ""20250304161603"", ""headline"": ""Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations"", ""summary"": ""Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine...""}, {""date"": ""20250304162400"", ""headline"": ""$20 Billion Club: For The Largest Corporate DB Plans, Maximizing Returns Is Not The Goal"", ""summary"": ""Russell Investments expects the trend toward liability-hedging fixed income to persist as funded status inches upward. We also expect ongoing interest in alternative asset classes.""}, {""date"": ""20250305090000"", ""headline"": ""The Dividend Aristocrats Ranked By Quality Scores: March 2025"", ""summary"": ""S&P Dow Jones Indices added three new members to the S&P 500 Dividend Aristocrats Index. Click here to find out my ranking of dividend aristocrats.""}, {""date"": ""20250305112432"", ""headline"": ""Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition"", ""summary"": ""JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033. Click here to read why JNJ is a Hold.""}, {""date"": ""20250305133100"", ""headline"": ""5 Big Biopharmaceutical Stocks That Are Finding Favor"", ""summary"": ""5 Big Biopharmaceutical Stocks That Are Finding Favor""}, {""date"": ""20250305153900"", ""headline"": ""Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out"", ""summary"": ""Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out""}, {""date"": ""20250305163103"", ""headline"": ""Johnson & Johnson to Host Investor Conference Call on First-Quarter Results"", ""summary"": ""Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, April 15th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk,...""}, {""date"": ""20250306070000"", ""headline"": ""10 Dividend Aristocrat Bargains To Help You SWAN During This Trade War Turmoil"", ""summary"": ""The trade war is causing market volatility. Read more about low-volatility dividend aristocrats offering stability in volatile markets.""}, {""date"": ""20250306172623"", ""headline"": ""J&J to stop studies of depression drug due to low effectiveness"", ""summary"": ""Johnson & Johnson will stoplate-stage studies of its experimental drug to treat majordepressive disorder due to a lack of sufficient efficacy, thedrug and medical device maker said on Thursday. ...""}, {""date"": ""20250306200000"", ""headline"": ""Finance Executives Seek Stability Amid Erratic Tariff Shifts"", ""summary"": ""Finance Executives Seek Stability Amid Erratic Tariff Shifts""}, {""date"": ""20250307093414"", ""headline"": ""Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors"", ""summary"": ""Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising for long-term investors.""}, {""date"": ""20250307105220"", ""headline"": ""Johnson & Johnson Statement on VENTURA Program"", ""summary"": ""TITUSVILLE, N.J- Johnson & Johnson has made the decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depressive disorder due to...""}, {""date"": ""20250308090000"", ""headline"": ""Johnson & Johnson Announces New Icotrokinra (JNJ-2113) Data from its Comprehensive Phase 3 Clinical Program"", ""summary"": ""Johnson & Johnson announced new icotrokinra data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis seeking to demonstrate the...""}, {""date"": ""20250309123323"", ""headline"": ""Intuitive Surgical: Getting Closed To Its Fair Value"", ""summary"": ""Intuitive Surgical is investing heavily in AI, AR, leading to future profitability. Learn why ISRG stock may present a buying opportunity.""}]",{}
18,2025-03-09,166.69000244140625,2025-03-16,162.80999755859375,-0.023276770208077502,D3,"[{""date"": ""20250309123323"", ""headline"": ""Intuitive Surgical: Getting Closed To Its Fair Value"", ""summary"": ""Intuitive Surgical is investing heavily in AI, AR, leading to future profitability. Learn why ISRG stock may present a buying opportunity.""}, {""date"": ""20250310080114"", ""headline"": ""Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients"", ""summary"": ""Topline results also show investigational\u00a0targeted oral peptide\u00a0icotrokinra\u00a0achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC...""}, {""date"": ""20250310083135"", ""headline"": ""Health Canada authorizes LAZCLUZE\u00ae (lazertinib) in combination with RYBREVANT\u00ae (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer"", ""summary"": ""Phase 3 MARIPOSA study showed\u00a0LAZCLUZE\u00ae plus RYBREVANT\u00ae significantly improved progression-free survival, reducing the risk of disease progression or death by 30 per cent versus osimertinib...""}, {""date"": ""20250310101946"", ""headline"": ""Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out"", ""summary"": ""Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out""}, {""date"": ""20250310104300"", ""headline"": ""Genmab Stops Blood Cancer Treatment Development After J&J Won't License It"", ""summary"": ""Genmab Stops Blood Cancer Treatment Development After J&J Won't License It""}, {""date"": ""20250310110100"", ""headline"": ""Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option"", ""summary"": ""Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option""}, {""date"": ""20250310123920"", ""headline"": ""Johnson & Johnson - Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis"", ""summary"": ""SPRING HOUSE - Johnson & Johnson today announced new icotrokinra data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis seeking...""}, {""date"": ""20250310230400"", ""headline"": ""Are High-Yield Dividend Stocks Best for Income-Focused Investors?"", ""summary"": ""Dividends come with many clear benefits, including a passive income stream and a shield against drawdowns in other positions.""}, {""date"": ""20250311090219"", ""headline"": ""Investigational plaque psoriasis treatments show promise in late-stage trials"", ""summary"": ""Newly released Phase III data illustrate potential of three drugs being investigated as treatments for plaque psoriasis\u2014namely two monoclonal antibodies and an oral peptide, from pharmaceutical...""}, {""date"": ""20250311110654"", ""headline"": ""Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded"", ""summary"": ""Investing.com -- Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their megablockbuster cancer drug, Darzalex.""}, {""date"": ""20250311123747"", ""headline"": ""J&J and Protagonist\u2019s icotrokinra scores in Phase IIb UC study"", ""summary"": ""GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of $2.19bn in 2030.""}, {""date"": ""20250311130205"", ""headline"": ""BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund"", ""summary"": ""BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.""}, {""date"": ""20250311132915"", ""headline"": ""Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success"", ""summary"": ""PTGX Achieves First Profit in 2024 Amid Clinical Milestones and Financial Turnaround""}, {""date"": ""20250311142018"", ""headline"": ""Genmab says J&J not exercising option on HexaBody-CD38"", ""summary"": ""Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38. \u201cWhile the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab\u2019s rigorous portfolio prioritization, Genmab will not pursue further clinical development of HexaBody-CD38,\u201d the company said in a state""}, {""date"": ""20250311160009"", ""headline"": ""Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It"", ""summary"": ""Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis. Click fo rmy PTGX update.""}, {""date"": ""20250311160754"", ""headline"": ""Is Johnson & Johnson (JNJ) the Best Low Risk Stock to Buy In 2025?"", ""summary"": ""We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other low risk stocks. Risk is a key consideration in investing and portfolio management, as investors generally aim to achieve the [\u2026]""}, {""date"": ""20250311161500"", ""headline"": ""PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study"", ""summary"": ""The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.""}, {""date"": ""20250311163254"", ""headline"": ""Legend Biotech's Carvykti Is Taking Off, And It's Still Early (Rating Upgrade)"", ""summary"": ""Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click for my updated look at LEGN earnings.""}, {""date"": ""20250311173630"", ""headline"": ""Johnson & Johnson (NYSE:JNJ) Reports Positive Phase 2b Trial Results For Ulcerative Colitis Treatment"", ""summary"": ""Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant announcements regarding its clinical trials, particularly the ANTHEM-UC study, which showcased promising results in ulcerative colitis treatment. These positive results provided a boost to investor confidence amid overall market volatility, triggered by economic concerns and trade issues, including tariffs announced by the Trump administration. The broader market faced a...""}, {""date"": ""20250312064719"", ""headline"": ""J&J Says CEO Joaquin Duato's 2024 Total Compensation Was $24.3 Million Versus $28.4 Million In 2023 - SEC Filing"", ""summary"": ""Johnson & Johnson: * J&J SAYS CEO JOAQUIN DUATO'S 2024 TOTAL COMPENSATION WAS$24.3MILLION VERSUS $28.4 MILLION IN 2023 \u2013 SEC FILINGSource text:Further company coverage: ...""}, {""date"": ""20250312100100"", ""headline"": ""Fidelity Select Health Care Portfolio Q4 2024 Review"", ""summary"": ""Health care stocks returned -9.75% in the final quarter of 2024, according to the MSCI U.S. IMI Health Care 25/50 Index, widely lagging the 2.41% gain of the broad-based S&P 500\u00c2\u00ae index.""}, {""date"": ""20250312100955"", ""headline"": ""J&J Medtech gets regulatory clearance for its latest robotic-assisted bronchoscopy technology"", ""summary"": ""Johnson & Johnson: * JOHNSON & JOHNSON MEDTECH ANNOUNCES CLEARANCE OF MONARCHTMQUESTFOR ENHANCED ROBOTIC-ASSISTED BRONCHOSCOPYSource text: https://shorturl.at/Z2FcFFurther company...""}, {""date"": ""20250312130011"", ""headline"": ""Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""20250312132907"", ""headline"": ""Caterpillar: Diversification Without Diworsification; Home Depot Looks Healthy, So Do Others"", ""summary"": ""Diversify Caterpillar holdings with tax-efficient strategies. Explore HD, LOW, and SNA for income replacement potential and strong dividend growth.""}, {""date"": ""20250312134713"", ""headline"": ""Johnson & Johnson (JNJ): Among Dobermans of the Dow to Buy"", ""summary"": ""We recently published a list of Dobermans of the Dow: 10 Stocks to Consider. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other Dobermans of the Dow to buy. The Dobermans of the Dow strategy serves as an alternative to the well-known Dogs of the [\u2026]""}, {""date"": ""20250312140011"", ""headline"": ""Johnson & Johnson : Meeting agenda (2025 Meeting agenda)"", ""summary"": ""Annual Shareholders Meeting April 24, 2025 Agenda Welcome 2024 Business Review ...""}, {""date"": ""20250312140012"", ""headline"": ""Johnson & Johnson : 2025 Proxy Statement and additional solicitation materials (Johnson Johnson 2025 Proxy)"", ""summary"": ""2025 Proxy Statement and Additional Definitive Proxy Solicitation Materials Definitive Proxy Statement, filed March 12, 2025 ...""}, {""date"": ""20250312182654"", ""headline"": ""Why Johnson & Johnson (JNJ) is the Best Pharma Stock to Buy According to Hedge Funds"", ""summary"": ""We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town in [\u2026]""}, {""date"": ""20250313100000"", ""headline"": ""J&J\u2019s Monarch robot wins FDA nod for AI software update"", ""summary"": ""Using Nvidia and GE Healthcare technology, the robotic surgery system is intended to help doctors\u00a0detect\u00a0lung cancer earlier.""}, {""date"": ""20250313101634"", ""headline"": ""FDA grants 510(k) clearance for J&J MedTech\u2019s Monarch Quest"", ""summary"": ""Monarch Quest provides physicians with a continuous vision.""}, {""date"": ""20250313172844"", ""headline"": ""Johnson & Johnson (NYSE:JNJ) Faces Shareholder Activism Over Human Rights and Executive Pay Proposals"", ""summary"": ""Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights assessments, with recommendations to vote against them at its annual meeting on April 24, 2025. This may have contributed to the company's recent 11% price increase over the last quarter. During the same period, Johnson & Johnson declared a cash dividend for the first quarter of 2025 and announced positive financial results, with Q4 sales rising to $22.52 billion...""}, {""date"": ""20250314001933"", ""headline"": ""Johnson & Johnson (JNJ): \u201cBreakout or Breakdown?\u201d \u2013 Jim Cramer Says JNJ Must Fall for Market to Bottom"", ""summary"": ""We recently published a list of Jim Cramer Discusses These 11 Stocks & Says Trump\u2019s \u2018Soft\u2019 On Tariffs Amidst $4 Trillion Wipeout. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In a recent appearance on CNBC\u2019s Squawk on the [\u2026]""}, {""date"": ""20250314040000"", ""headline"": ""Honeywell's Planned Spinoff And What It Means Amid Macro Volatility"", ""summary"": ""After a slew of generally successful spinoffs elsewhere in the market, Honeywell looks to split into three units. Read more here.""}, {""date"": ""20250314090114"", ""headline"": ""Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks"", ""summary"": ""As the craze of earnings season draws to a close, here\u2019s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN).""}, {""date"": ""20250314093000"", ""headline"": ""Big Pharma Walked Away From Mental Health. Why Some Are Coming Back."", ""summary"": ""Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving interest.""}, {""date"": ""20250314135500"", ""headline"": ""Zimmer Biomet Focuses on Innovation Amid Growing Competition"", ""summary"": ""Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention.""}, {""date"": ""20250314142631"", ""headline"": ""Hostage to Legal Decisions \u2013 Here\u2019s Why Jim Cramer Gave Up on Johnson & Johnson (JNJ)"", ""summary"": ""We recently published a list of Was Jim Cramer Right About These 16 Stocks?. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed 12 months ago during his show on March 18, 2024. On the most recent episode of Mad [\u2026]""}, {""date"": ""20250314143024"", ""headline"": ""Genmab: GEN3014's Demise And Implications For The HexaBody Platform"", ""summary"": ""Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an analysis of GMAB stock now.""}, {""date"": ""20250314154505"", ""headline"": ""Johnson & Johnson (JNJ) Could Be a Great Choice"", ""summary"": ""Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.""}, {""date"": ""20250316134003"", ""headline"": ""Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'"", ""summary"": ""Discover why Johnson & Johnson and Kenvue offer resilient defensive stocks with high dividends.""}]",{}
19,2025-03-16,162.80999755859375,2025-03-23,163.6300048828125,0.005036590728549228,U1,"[{""date"": ""20250316134003"", ""headline"": ""Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'"", ""summary"": ""Discover why Johnson & Johnson and Kenvue offer resilient defensive stocks with high dividends.""}, {""date"": ""20250317225823"", ""headline"": ""Why Organon Is A Top Pick For Income Investors"", ""summary"": ""In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.""}, {""date"": ""20250318080406"", ""headline"": ""Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sj\u00f6gren's disease, has now received Fast Track designation"", ""summary"": ""Sj\u00f6gren's disease \u00a0is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments\u00a0\u00a0The Company is actively enrolling patients in the Phase 3 DAFFODIL study\u00a0\u00a0This...""}, {""date"": ""20250318125835"", ""headline"": ""Widely used drugs on US imports list from Europe"", ""summary"": ""Widely used prescription medicinescould get caught up in the Trump administration's tariff tradewars and EU retaliation. The following is a list of major prescription drugs whoseingredients or...""}, {""date"": ""20250318210100"", ""headline"": ""Top Stock Reports for Visa, Johnson & Johnson & Thermo Fisher Scientific"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Johnson & Johnson (JNJ) and Thermo Fisher Scientific Inc. (TMO), as well as a micro-cap stock AMREP Corporation (AXR).""}, {""date"": ""20250319090000"", ""headline"": ""The Zacks Analyst Blog Highlights Visa, Johnson & Johnson, Thermo Fisher and AMREP"", ""summary"": ""Visa, Johnson & Johnson, Thermo Fisher and AMREP are included in this Analyst Blog.""}, {""date"": ""20250319145900"", ""headline"": ""JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease"", ""summary"": ""The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease in adults.""}, {""date"": ""20250320094048"", ""headline"": ""My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 11 Buys"", ""summary"": ""February investments fell below $1,000, mainly in BDCs like Owl Rock Capital and Ares Capital, boosting annual dividend income by $77.""}, {""date"": ""20250320112033"", ""headline"": ""Defensive Stocks For Unpredictable Trump Policy"", ""summary"": ""Navigate market volatility with defensive stocks, bonds, and gold.""}, {""date"": ""20250320120000"", ""headline"": ""RYBREVANT\u00ae (amivantamab-vmjw) plus LAZCLUZE\u2122 (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025"", ""summary"": ""Johnson & Johnson (NYSE:JNJ) announced today that new data from its industry-leading oncology pipeline will be presented at the 2025 European Lung Cancer Congress (ELCC), including overall survival (OS) results from the Phase 3 MARIPOSA study evaluating RYBREVANT\u00ae (amivantamab-vmjw) plus LAZCLUZE\u2122 (lazertinib) versus osimertinib in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 delet""}, {""date"": ""20250320200500"", ""headline"": ""Historic Dividend Outperformance"", ""summary"": ""For year to date performance, the biggest losers are now mostly growth factors, whereas low volatility and dividend focused ETFs are actually still in the green so far in 2025.""}, {""date"": ""20250320221200"", ""headline"": ""U.S. FDA approves TREMFYA\u00ae (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA\u00ae (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for the treatment of adults with moderately to severely active Crohn's disease (CD), a chronic inflammatory condition of the gastrointestinal tract.1 This milestone builds upon the FDA approval of TREMFYA\u00ae in moderately to severely active ulcerative colitis (UC)""}, {""date"": ""20250321060355"", ""headline"": ""Johnson & Johnson Increases US Investment To More Than $55 Bln Over The Next Four Years"", ""summary"": ""Johnson & Johnson: * JOHNSON & JOHNSON INCREASES U.S. INVESTMENT TO MORE THAN$55BILLION OVER THE NEXT FOUR YEARS * JOHNSON & JOHNSON - INVESTMENT REPRESENTS 25%...""}, {""date"": ""20250321061213"", ""headline"": ""J&J plans to invest more than $55 billion in US over next four years"", ""summary"": ""Johnson & Johnson said onFriday it plans to invest more than $55 billion over the nextfour years to build manufacturing facilities and researchinfrastructure in the United States. The...""}, {""date"": ""20250321072147"", ""headline"": ""Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy"", ""summary"": ""Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.""}, {""date"": ""20250321081015"", ""headline"": ""PBMs Are Becoming Legal Risks For Employers"", ""summary"": ""JPMorgan Chase & Co. is the latest major corporation to face a class action lawsuit from employees alleging mismanagement of their prescription drug benefits. The lawsuit claims that JPMorgan, through...""}, {""date"": ""20250321081240"", ""headline"": ""U.S. FDA approves TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease"", ""summary"": ""HORSHAM - Johnson & Johnson today announced that the U.S. Food and Drug Administration has approved TREMFYA , the first and only IL-23 inhibitor offering both subcutaneous and intravenous ...""}, {""date"": ""20250321092028"", ""headline"": ""FDA approves Johnson & Johnson\u2019s Tremfya to treat Crohn\u2019s disease"", ""summary"": ""The decision is based on outcomes from Phase III trials involving 1,300 CD subjects.""}, {""date"": ""20250321100000"", ""headline"": ""Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years"", ""summary"": ""NEW BRUNSWICK, N.J., March 21, 2025--Today, Johnson & Johnson (NYSE: JNJ) (the \""Company\""), healthcare\u2019s leading, most comprehensive innovation powerhouse, announced manufacturing, research and development, and technology investments of more than $55 billion in the United States over the next four years. This represents a 25% increase in investment compared to the previous four years and builds upon the Company\u2019s already elevated U.S. investment levels resulting from the passage of the 2017 Tax C""}, {""date"": ""20250321100753"", ""headline"": ""J&J boosts US investments by 25% over 4 years amid looming tariff threats"", ""summary"": ""Johnson & Johnson has laid out plans to raise U.S. investments by 25% to more than $55 billion over the next four years, as a threat of drug import duties by the Trump administration compels companies to expand their manufacturing operations domestically.  The pharmaceutical giant said on Friday it planned to build four new plants as part of its investment, one of which would be set up in Wilson, North Carolina, where it officially broke ground earlier in the day.  J&J did not disclose where it plans to build the other plants.""}, {""date"": ""20250321100853"", ""headline"": ""J&J boosts US manufacturing as big pharma reshores"", ""summary"": ""Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.""}, {""date"": ""20250321101112"", ""headline"": ""How Understanding Bankruptcy Trends Can Benefit Your Business"", ""summary"": ""The bankruptcy legal landscape presents both challenges and opportunities for businesses navigating financial distress. Understanding current bankruptcy trends can help businesses make more informed...""}, {""date"": ""20250321114136"", ""headline"": ""Johnson & Johnson plans $55 billion in US investments over the next four years"", ""summary"": ""Johnson & Johnson says it will invest more than $55 billion within the United States over the next four years, including four new manufacturing plants.  A number of companies have highlighted investments in the U.S. in recent months, a focus of Trump administration.  J&J rival Eli Lilly and Co. announced in late February that it planned to build four new factories in the U.S. Both Lilly and J&J cited tax cut legislation passed in 2017 as factors in their U.S. investments.""}, {""date"": ""20250321122336"", ""headline"": ""FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease"", ""summary"": ""On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson\u2019s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV) induction options, for adults with moderately to severely active Crohn\u2019s disease (CD), a chronic inflammatory condition of the gastrointestinal tract. This approval is supported by results from multiple Phase 3 trials evaluating more than 1,300 patients with moderately to severely active CD who fa""}, {""date"": ""20250321122800"", ""headline"": ""J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease"", ""summary"": ""FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.""}, {""date"": ""20250321124314"", ""headline"": ""Investing in the U.S.: Tracking Corporate Spending Pledges Under Trump"", ""summary"": ""Johnson & Johnson said Friday it would invest more than $55 billion in the U.S. in the next few years, adding to a series of commitments by big corporations.  ? CMA CGM: The French shipping company, led by Rodolphe Saad\u00e9, aims to invest $20 billion in the U.S., creating 10,000 jobs. CMA CGM will triple its U.S.-flagged fleet, upgrade port facilities and create a Chicago airfreight hub.  ? Eli Lilly: The drugmaker behind Zepbound and Mounjaro plans to invest $27 billion building four new manufacturing plants in the U.S. Lilly expects the project will create 3,000 high-skilled jobs and employ 10,000 construction workers.""}, {""date"": ""20250321125951"", ""headline"": ""2025 Dividend Kings: Strong Run Continues"", ""summary"": ""Discover the top-performing Dividend Kings of 2025, outperforming the S&P 500 by 4.57%. Click here to explore more promising picks.""}, {""date"": ""20250321140900"", ""headline"": ""Johnson & Johnson to Invest Over $55 Billion in U.S. in Next Four Years"", ""summary"": ""Johnson & Johnson said it is increasing U.S investments to more than $55 billion over the next four years, boosting spending on manufacturing, R&D and technology.""}, {""date"": ""20250321150446"", ""headline"": ""Johnson & Johnson Boosts Planned US Investment to More Than $55 Billion"", ""summary"": ""Johnson & Johnson (JNJ) said Friday that it plans to increase its US investment to more than $55 bil""}, {""date"": ""20250321150559"", ""headline"": ""J&J is latest company trying to get on Trump's good side with big U.S. investment"", ""summary"": ""Investing.com -- Pharmaceutical giant Johnson&Johnson became the latest company to announce a massive investment in the U.S. to appease President Donald Trump.""}, {""date"": ""20250321160137"", ""headline"": ""Top Midday Stories: Boeing Wins Multibillion Dollar Contract to Build Fighter Jet; FedEx Shares Fall on Earnings Miss, Downbeat Guidance"", ""summary"": ""All three major US stock indexes were down in midday trading as markets appear as though they will e""}, {""date"": ""20250321182247"", ""headline"": ""J&J boosts US operations with $55bn investment"", ""summary"": ""J&J is the latest pharma company to announce a major US investment, committing to a $55bn influx in the next four years.""}, {""date"": ""20250321184100"", ""headline"": ""Johnson & Johnson is the latest pharma giant to court Trump with new investment plans"", ""summary"": ""Johnson & Johnson (JNJ) is joining Eli Lilly (LLY) in attempting to court favor with President Donald Trump by announcing plans to expand its manufacturing footprint in the United States.""}, {""date"": ""20250321190200"", ""headline"": ""Ranking the S&P 500s Most Defensive Stocks"", ""summary"": ""Ranking the S&P 500s Most Defensive Stocks""}, {""date"": ""20250322015000"", ""headline"": ""The Davenport Insider Buying Fund Q4 2024 Commentary"", ""summary"": ""The Davenport Insider Buying Fund (DBUYX) declined -2.24% during the fourth quarter compared to a 2.41% gain for the S&P 500\u00c2\u00ae Index. Click here to read the full commentary. ""}, {""date"": ""20250322180000"", ""headline"": ""2 Dividend Picks Yielding Up To 5.67% For A Balanced Income & Growth Portfolio"", ""summary"": ""I have added Canadian Natural Resources and NextEra Energy to The Dividend Income Accelerator Portfolio, each representing 2.19% of our overall portfolio.""}, {""date"": ""20250322190626"", ""headline"": ""Was Jim Cramer Right About Johnson & Johnson (JNJ)?"", ""summary"": ""We recently published a list of Did Jim Cramer Get These 23 Stocks Right?. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed 12 months ago. In a recent appearance on CNBC\u2019s Squawk on the Street, Jim Cramer commented on [\u2026]""}]",{}
20,2025-03-23,163.6300048828125,2025-03-30,163.7100067138672,0.0004889190775980712,U1,"[{""date"": ""20240724153000"", ""headline"": ""Spinoffs Can Pay Juicy Dividends. 6 Ones to Play."", ""summary"": ""Spinoffs Can Pay Juicy Dividends. 6 Ones to Play.""}, {""date"": ""20250324053225"", ""headline"": ""Johnson & Johnson Increases U.S. Investment to More than $55 Billion over the Next Four Years"", ""summary"": ""NEW BRUNSWICK - Johnson & Johnson , healthcare's leading, most comprehensive innovation powerhouse, announced manufacturing, research and development, and technology investments of more than $55...""}, {""date"": ""20250324103100"", ""headline"": ""Here's How to Play JNJ Stock as it Announces $55B US Investment Plan"", ""summary"": ""Those who own JNJ stock may stay invested for some time, as the company is optimistic about a better performance in 2025.""}, {""date"": ""20250324114722"", ""headline"": ""Johnson & Johnson to break ground on new state-of-the-art biologics facility in North Carolina to deliver market-leading portfolio of transformational therapies"", ""summary"": ""New Brunswick, N.J., - Johnson & Johnson today will break ground on its new, 500,000 square foot, state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which will expand its...""}, {""date"": ""20250324123900"", ""headline"": ""Take the Zacks Approach to Beat the Markets: CMS Energy, Chevron, AutoZone in Focus"", ""summary"": ""Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.""}, {""date"": ""20250324131442"", ""headline"": ""Is Johnson & Johnson (JNJ) The Best Healthcare Dividend Stock to Invest in?"", ""summary"": ""We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best healthcare dividend stocks to invest in. The US healthcare sector has been at the forefront since the emergence of COVID-19 in [\u2026]""}, {""date"": ""20250324135632"", ""headline"": ""Argenx: The Magic May Be Already Priced In"", ""summary"": ""Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ARGX stock here.""}, {""date"": ""20250324190000"", ""headline"": ""ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?"", ""summary"": ""AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.""}, {""date"": ""20250324214517"", ""headline"": ""Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts"", ""summary"": ""The latest trading day saw Johnson & Johnson (JNJ) settling at $163.29, representing a -0.21% change from its previous close.""}, {""date"": ""20250324230600"", ""headline"": ""Wasatch Global Value Fund Q4 2024 Commentary"", ""summary"": ""The Wasatch Global Value Fund\u00e2\u0080\u0094Investor Class returned -5.78% in the fourth quarter of 2024, underperforming the MSCI AC (All Country) World Value Index, which lost -4.71%.""}, {""date"": ""20250325095406"", ""headline"": ""Johnson & Johnson : MedTech Launches the DUALTO\u2122 Energy System for Use Across Surgical Treatment Approaches"", ""summary"": ""New Brunswick, NJ - March 25, 2025 - Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, today announced the launch of the DUALTO\u2122 Energy System, a surgical solution...""}, {""date"": ""20250326120300"", ""headline"": ""New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)"", ""summary"": ""Johnson & Johnson (NYSE: JNJ) announced today that 12 abstracts, including two oral presentations, highlighting the Company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia gravis (gMG), will be presented at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5 \u2013 9 in San Diego, California.""}, {""date"": ""20250326121849"", ""headline"": ""Johnson & Johnson MedTech introduces electrosurgical generator"", ""summary"": ""The solution is designed for future compatibility with the company's Ottava Robotic Surgical System.""}, {""date"": ""20250326130005"", ""headline"": ""These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar"", ""summary"": ""The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.""}, {""date"": ""20250326133702"", ""headline"": ""J&J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib"", ""summary"": ""Johnson & Johnson: * RYBREVANT\u00ae PLUS LAZCLUZE\u2122 OUTPERFORMS OSIMERTINIB WITH A SIGNIFICANT AND UNPRECEDENTEDOVERALL SURVIVAL BENEFIT IN PATIENTS WITH EGFR-MUTATED NON-SMALLCELL...""}, {""date"": ""20250326134010"", ""headline"": ""Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock"", ""summary"": ""Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.""}, {""date"": ""20250326154500"", ""headline"": ""RYBREVANT\u00ae (amivantamab-vmjw) plus LAZCLUZE\u2122 (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer"", ""summary"": ""Johnson & Johnson (NYSE:JNJ) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed RYBREVANT\u00ae (amivantamab-vmjw) plus LAZCLUZE\u2122 (lazertinib) significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substi""}, {""date"": ""20250326163729"", ""headline"": ""Johnson & Johnson Reports Positive Data from Phase 3 Study of Lung Cancer Drug Candidate"", ""summary"": ""Johnson & Johnson (JNJ) said Wednesday that results from a phase 3 trial showed that Rybrevant as a""}, {""date"": ""20250326180000"", ""headline"": ""Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns"", ""summary"": ""The Dividend Income Accelerator Portfolio focuses on financially healthy companies with strong balance sheets. Check out the recent additions to the portfolio.""}, {""date"": ""20250326194011"", ""headline"": ""Jim Cramer Highlights Johnson & Johnson (JNJ) as a Rare Winner Amid Market Sell-Off"", ""summary"": ""We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his frustration on March 19 about how investors often [\u2026]""}, {""date"": ""20250327021007"", ""headline"": ""Plaintiffs Double Down On Challenges To PBM Arrangements In Class Action Lawsuits Involving Johnson & Johnson And JPMorganChase"", ""summary"": ""On March 10, 2024, the plaintiffs filed an amended complaint in a much-followed putative class action lawsuit against Johnson & Johnson alleging that the plan fiduciaries for J&J's group health plan...""}, {""date"": ""20250327092500"", ""headline"": ""2 Recession-Proof Dividend Stocks to Buy and Hold"", ""summary"": ""Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are excellent examples along those lines.  Medtronic and Johnson & Johnson provide some of these products and services.  Medtronic is one of the largest medical device companies in the world.""}, {""date"": ""20250327121957"", ""headline"": ""J&J\u2019s NSCLC combo projected to extend survival by one year over Tagrisso"", ""summary"": ""The Rybrevant and Lazcluze combination reduced the risk of death by 25% compared to AstraZeneca\u2019s Tagrisso.""}, {""date"": ""20250327130016"", ""headline"": ""Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""20250327141304"", ""headline"": ""How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain"", ""summary"": ""Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a \""wait-and-see\"" pattern.""}, {""date"": ""20250327155009"", ""headline"": ""J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study"", ""summary"": ""Johnson & Johnson announced results for the \u201cgold standard endpoint in cancer treatment\u201d of overall survival from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed Rybrevant plus Lazcluze significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations. Median OS is projected to exceed one year beyond the median o""}, {""date"": ""20250327172106"", ""headline"": ""Johnson & Johnson (NYSE:JNJ) Presents Promising Nipocalimab Data At AAN Annual Meeting"", ""summary"": ""Johnson & Johnson (NYSE:JNJ) experienced an 11% price increase over the last quarter. This movement coincided with several corporate developments, including the presentation of breakthrough research on nipocalimab at the American Academy of Neurology meeting, and the announcement of FDA fast track designations for its treatments. Additionally, the potential acquisition talks of Intra-Cellular Therapies and strong sales figures in Q4 2024 were pivotal in maintaining investor interest. Launches...""}, {""date"": ""20250327204750"", ""headline"": ""Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q4 2024 Update"", ""summary"": ""AQR Capital Management's portfolio grew to $77.63B with top stakes in Apple, Nvidia, Microsoft, Amazon and Alphabet. Read here for a portfolio update.""}, {""date"": ""20250328091157"", ""headline"": ""2 Reasons to Like JNJ and 1 to Stay Skeptical"", ""summary"": ""Since September 2024, Johnson & Johnson has been in a holding pattern, posting a small return of 0.7% while floating around $163.19.""}, {""date"": ""20250328094130"", ""headline"": ""Johnson & Johnson MedTech to Highlight Latest Advancements in Heart Disease Treatment with Impella at ACC.25"", ""summary"": ""Danvers - Johnson & Johnson MedTech, the global leader in heart recovery, will feature the latest evidence demonstrating the survival benefit of Impella heart pump technology at the American College...""}, {""date"": ""20250328144100"", ""headline"": ""J&J launches energy generator compatible with Ottava robot"", ""summary"": ""Johnson & Johnson said\u00a0the Dualto energy system\u2019s design allows for up to 46% less footprint than separate generators.""}, {""date"": ""20250328161839"", ""headline"": ""Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case"", ""summary"": ""A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally promoting the HIV drugs Prezista and Intelence.  U.S. District Judge Zahid Quraishi in Trenton, New Jersey, ordered the drugmaker's Janssen unit to pay $360 million for violating the federal False Claims Act.  He also imposed $1.28 billion in civil fines, or $8,000 for each of 159,574 false claims the jury found were submitted to programs such as Medicare, Medicaid and the AIDS Drug Assistance Program.""}, {""date"": ""20250328164023"", ""headline"": ""Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)"", ""summary"": ""Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D investments. Read what could be next for shares in this healthcare giant.""}, {""date"": ""20250328195533"", ""headline"": ""Sector Update: Health Care Stocks Softer Late Afternoon"", ""summary"": ""Health care stocks eased late Friday afternoon, with the NYSE Health Care Index down 0.1% and the He""}, {""date"": ""20250329070000"", ""headline"": ""If I Could Only Choose 5 Dividend Stocks For My Retirement Portfolio"", ""summary"": ""Focus on companies with strong balance sheets and sustainable dividends for retirement. See why these five stocks offer great risk-reward and growth potential.""}, {""date"": ""20250329104500"", ""headline"": ""3 Relatively Safe Stocks to Buy Right Now"", ""summary"": ""Investing in stocks comes with risks.  David Jagielski (Abbott Laboratories): If you're looking for safety within the healthcare sector, a top name to consider right now is Abbott Laboratories.  For starters, it offers an above-average dividend yield of 1.9% (the S&P 500 average is 1.4%).""}, {""date"": ""20250329135441"", ""headline"": ""Jim Cramer on Johnson & Johnson (NYSE:JNJ): Their Spinoff Was Ill-Advised"", ""summary"": ""We recently published a list of Jim Cramer Says Trump\u2019s Tariff Strategy Is Working & Discusses These 11 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC\u2019s Squawk on the Street, Jim Cramer [\u2026]""}, {""date"": ""20250330060000"", ""headline"": ""Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors"", ""summary"": ""Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.""}, {""date"": ""20250330185213"", ""headline"": ""Procter & Gamble, Johnson & Johnson Among 10 Companies To Announce Dividend Increases In First Half Of April"", ""summary"": ""Discover predictions for upcoming dividend increases from top companies with long-term growth. Learn which stocks to watch this April.""}]",{}
